<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Conventional cytotoxic agents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Conventional cytotoxic agents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Conventional cytotoxic agents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Justin Floyd, DO</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas Archibald Kerr, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Reed E Drews, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keith D Lindor, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Patients undergoing chemotherapy for cancer using conventional cytotoxic agents, molecularly targeted agents, and immunotherapeutic agents, require careful assessment of liver function both prior to and during therapy. Potential interactions between the liver and chemotherapy fall into two categories:</p><p class="bulletIndent1"><span class="glyph">●</span>Direct chemotherapy-induced hepatotoxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Potentiation of preexisting liver disease, especially viral hepatitis. Altered hepatic drug metabolism due to underlying liver disease can result in higher or more persistent drug levels, thereby causing increased systemic toxicity (particularly myelosuppression) or worsening of liver function because of chemotherapy-induced hepatotoxicity.</p><p></p><p>The interrelationship between the liver and cytotoxic chemotherapy agents is reviewed here. The interrelationship between the liver and molecularly targeted agents used for cancer therapy are discussed elsewhere, as is hepatotoxicity associated with checkpoint inhibitor immunotherapy, as used for advanced melanoma and other solid tumors. (See  <a class="medical medical_review" href="/d/html/128144.html" rel="external">"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Molecularly targeted agents"</a> and  <a class="medical medical_review" href="/d/html/134862.html" rel="external">"Hepatic, pancreatic, and rare gastrointestinal complications of immune checkpoint inhibitor therapy", section on 'Hepatotoxicity'</a>.)</p><p>General aspects of drug metabolism and patterns of hepatic injury are discussed separately, as is reactivation of hepatitis B (HBV) viral infection in patients treated with immunosuppressive therapy. (See  <a class="medical medical_review" href="/d/html/3568.html" rel="external">"Drugs and the liver: Metabolism and mechanisms of injury"</a> and  <a class="medical medical_review" href="/d/html/3571.html" rel="external">"Drug-induced liver injury"</a> and  <a class="medical medical_review" href="/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GENERAL ASPECTS OF CHEMOTHERAPY-INDUCED HEPATOTOXICITY</span></p><p class="headingAnchor" id="H3"><span class="h2">Mechanisms</span><span class="headingEndMark"> — </span>Most hepatotoxic drug reactions are idiosyncratic and classified mechanistically either as immunologic (hypersensitivity) or metabolic [<a href="#rid1">1</a>]. These reactions typically are neither dose dependent nor predictable. (See  <a class="medical medical_review" href="/d/html/3568.html" rel="external">"Drugs and the liver: Metabolism and mechanisms of injury", section on 'Mechanisms of drug-induced hepatotoxicity'</a>.)</p><p>While the reaction to many chemotherapy drugs is manifested by hepatocellular injury, inflammation, and/or cholestasis, other agents cause endothelial damage or thrombosis leading to vascular complications such as hepatic veno-occlusive disease (VOD, also called hepatic sinusoidal obstruction syndrome [SOS]). (See <a class="local">'Hepatic vascular injury'</a> below.)</p><p class="headingAnchor" id="H2739719"><span class="h3">Liposomal drug formulations</span><span class="headingEndMark"> — </span>Liposomal drug delivery systems have been utilized to improve the pharmacologic characteristics of chemotherapeutics and antibiotics, and improve drug delivery to optimal sites of action. Nevertheless, concerns have been raised about altered toxicity profiles with these preparations relative to non-encapsulated drug forms:</p><p class="bulletIndent1"><span class="glyph">●</span>In a case control study of patients undergoing hematopoietic cell transplant, use of <a class="drug drug_general" data-topicid="9499" href="/d/drug information/9499.html" rel="external">liposomal amphotericin B</a> (L-AMB) was associated with a <strong>higher</strong> rate of elevated liver enzymes compared with conventional <a class="drug drug_general" data-topicid="8701" href="/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> (AMB-D) [<a href="#rid2">2</a>]. However, an autopsy study of 64 patients treated before death with either L-AMB or <a class="drug drug_general" data-topicid="8724" href="/d/drug information/8724.html" rel="external">amphotericin B lipid complex</a> (ABLC) failed to reveal any clear histologic evidence of hepatotoxicity in either group, despite well-characterized elevations in liver enzymes with administration of these medicines [<a href="#rid3">3</a>]. These data suggest that elevated liver enzymes associated with liposomal drug formulations such as amphotericin B may not reflect severe histologic injury.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On the other hand, animal studies have suggested that sterically stabilized liposomal encapsulation of <a class="drug drug_general" data-topicid="9612" href="/d/drug information/9612.html" rel="external">6-mercaptopurine</a> (6-MP) is associated with decreased hepatoxicity compared with conventional liposomal formulations [<a href="#rid4">4</a>].</p><p></p><p>As liposomal drug delivery approaches become more common and diverse, patterns of hepatotoxicity may be altered.</p><p class="headingAnchor" id="H4"><span class="h3">Hepatic vascular injury</span><span class="headingEndMark"> — </span>SOS, previously called VOD, is a pattern of liver injury that is caused by nonthrombotic obliteration of small intrahepatic veins by subendothelial fibrin. SOS is associated with congestion and potentially fatal necrosis of centrilobular hepatocytes.</p><p>SOS occurs most frequently in patients undergoing hematopoietic cell transplantation. Most cases are thought to be drug-induced, and the drugs most commonly implicated are those that undergo hepatic metabolism. (See  <a class="medical medical_review" href="/d/html/129806.html" rel="external">"Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults", section on 'Introduction'</a> and  <a class="medical medical_review" href="/d/html/129806.html" rel="external">"Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults"</a>.)</p><p>SOS has occasionally been reported with non-myeloablative doses of <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a> (DTIC) [<a href="#rid5">5-11</a>], including patients treated with ABVD (<a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a>, DTIC) for Hodgkin lymphoma [<a href="#rid12">12,13</a>], and with <a class="drug drug_general" data-topicid="9318" href="/d/drug information/9318.html" rel="external">dactinomycin</a> [<a href="#rid11">11</a>], 6-thioguanine (6-TG) or 6-MP [<a href="#rid14">14,15</a>], and <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> (AZ) [<a href="#rid16">16,17</a>].</p><p><a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">Oxaliplatin</a> is associated with a dose-dependent pattern of hepatic sinusoidal injury, similar to SOS, which can be identified radiographically by the development of splenomegaly resulting from an increase in portal venous pressure [<a href="#rid18">18-22</a>]. The manifestations of this toxicity are best described in the adjuvant setting, where approximately 45 percent of patients who have received six months of treatment with an oxaliplatin-containing regimen develop splenomegaly with resultant reductions in platelet counts that tend to normalize within approximately two years [<a href="#rid18">18</a>]. Most of these patients do not develop a clinical picture of cirrhosis over time. (See  <a class="medical medical_review" href="/d/html/3580.html" rel="external">"Noncirrhotic portal hypertension", section on 'Idiopathic noncirrhotic portal hypertension/Porto-sinusoidal vascular disease'</a>.) </p><p>The potential clinical impact of hepatic sinusoidal injury is best described in patients undergoing hepatic metastasectomy for colorectal cancer liver metastases; patients who receive preoperative chemotherapy with regimens containing <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> have increased bleeding risk and postoperative morbidity. Findings at the time of liver resection include steatosis, hepatic vascular injury, and nodular regenerative hyperplasia (now termed idiopathic noncirrhotic portal hypertension [including nodular regenerative hyperplasia]). Because of this injury pattern, it is generally recommended that the duration of neoadjuvant therapy be limited to the fewest number of cycles needed to render patients resectable. Concomitant administration of <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> may protect against the development of oxaliplatin-induced hepatic sinusoidal injury, although the data are mixed. (See  <a class="medical medical_review" href="/d/html/2483.html" rel="external">"Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Post-treatment assessment and duration of neoadjuvant therapy'</a>.)</p><p>A similar pattern of hepatic vascular injury with steatosis is reported in patients receiving preoperative therapy with combinations of <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> and FU prior to the resection of liver metastases. As with <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> combinations, it is generally recommended that the duration of neoadjuvant therapy be limited to the fewest number of cycles needed to render patients resectable. (See <a class="local">'Irinotecan and liposomal irinotecan'</a> below and  <a class="medical medical_review" href="/d/html/2483.html" rel="external">"Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Post-treatment assessment and duration of neoadjuvant therapy'</a>.) </p><p class="headingAnchor" id="H5"><span class="h3">Irradiation plus chemotherapy</span><span class="headingEndMark"> — </span>Although radiation to the liver is itself hepatotoxic, otherwise tolerable doses of radiation therapy to the right upper quadrant can induce severe hepatic injury when combined with systemic doses of normally nonhepatotoxic chemotherapeutic agents. This has been described most often in patients treated concurrently with hepatic radiation and <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> [<a href="#rid23">23,24</a>], <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> [<a href="#rid25">25</a>], and <a class="drug drug_general" data-topicid="9318" href="/d/drug information/9318.html" rel="external">dactinomycin</a>. (See <a class="local">'Dactinomycin'</a> below.)</p><p>In an illustrative series, 35 patients with lymphoma received concurrent monthly <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> and relatively low-dose liver irradiation (total dose, 15 to 25 Gy) [<a href="#rid23">23</a>]. Ten of 35 patients developed severe hepatotoxicity (aspartate transaminase [AST] greater than three times normal, clinical evidence of liver failure, one fatal), and nine had moderate toxicity.</p><p>Reactivation or exacerbation of radiation-induced hepatic damage is a likely mechanism since all of these drugs have been associated with a radiation "recall" reaction in previously irradiated tissues. (See  <a class="medical medical_review" href="/d/html/2090.html" rel="external">"Cutaneous adverse effects of conventional chemotherapy agents", section on 'Radiation recall dermatitis and radiation enhancement'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Clinical presentation and diagnosis</span><span class="headingEndMark"> — </span>The clinical presentation of chemotherapy-related hepatotoxicity can range from asymptomatic biochemical abnormalities to an acute illness with jaundice that resembles viral hepatitis [<a href="#rid26">26</a>].</p><p>The severity of liver injury is primarily assessed by measurement of gamma-glutamyl transpeptidase (GGT), the serum aminotransferases (AST and alanine aminotransferase [ALT]), bilirubin, and alkaline phosphatase. The pattern of abnormalities on these tests is more informative than elevation of any individual test. Elevation of aminotransferases (AST, ALT) typically indicates hepatocellular injury, while increases in bilirubin and alkaline phosphatase suggest cholestasis. (See  <a class="medical medical_review" href="/d/html/3573.html" rel="external">"Overview of liver biochemical tests"</a>.)</p><p>Standardized criteria have been developed by the National Cancer Institute (NCI) and World Health Organization (WHO) to quantify or grade the severity of treatment-related abnormalities in the liver function tests (LFTs) in patients undergoing chemotherapy  (<a class="graphic graphic_table graphicRef77533" href="/d/graphic/77533.html" rel="external">table 1</a>).</p><p>The differential diagnosis includes progressive tumor, exacerbation of coexisting hepatic disease, reactivation of chronic viral hepatitis, and adverse effects of other drugs which produce similar clinical features and abnormalities in the LFTs [<a href="#rid27">27,28</a>]. The distinction between drug-induced hepatotoxicity due to chemotherapy and other causes of liver injury can be difficult. Features suggesting toxicity due to chemotherapy include lack of prior illness, clinical symptoms or biochemical abnormalities developing after drug administration, and improvement after discontinuation of the cytotoxic agent. (See <a class="local">'Impact of preexisting liver disease'</a> below.)</p><p>Testing for hepatitis A, B, C, and sometimes cytomegalovirus (CMV) is commonly sent to evaluate for infectious causes of elevated liver enzymes. Abdominal ultrasound or computed tomography (CT) may be needed to differentiate drug toxicity from biliary, vascular, or tumor-related conditions. A liver biopsy is seldom necessary to characterize or stage acute hepatotoxicity [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests"</a> and  <a class="medical medical_review" href="/d/html/3587.html" rel="external">"Approach to liver biopsy"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Natural history</span><span class="headingEndMark"> — </span>The natural history of chemotherapy hepatotoxicity is variable. Some agents cause reversible toxicity while others are associated with a progressive course that can lead to fibrosis or cirrhosis despite drug discontinuation. If the damage is reversible after withholding of the offending agent, toxicity will generally recur upon reintroduction of the offending agent. Dose reduction for subsequent courses or permanent discontinuation of the drug may be advised, depending on the specific agent, and the severity of the hepatotoxicity. If the reaction was immunologically based (eg, a true hypersensitivity reaction accompanied by rash, eosinophilia), rechallenge is usually not recommended. (See <a class="local">'Dacarbazine'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h2">Impact of preexisting liver disease</span><span class="headingEndMark"> — </span>Susceptibility to chemotherapy-induced liver injury may be increased by the presence of hepatobiliary metastases, immune compromise, chronic liver disease including viral/autoimmune hepatitis, nutritional deficiencies, or the use of <a class="drug drug_general" data-topicid="10307" href="/d/drug information/10307.html" rel="external">parenteral nutrition</a>.</p><p>Patients with a preexisting liver disease should undergo a full diagnostic workup prior to chemotherapy to elucidate the cause and severity of the liver disease. Therapy of any coexisting liver disorder should be optimized to minimize the potential for chemotherapy-induced complications. (See  <a class="medical medical_review" href="/d/html/3576.html" rel="external">"Approach to the patient with abnormal liver biochemical and function tests"</a>.)</p><p>Clinical decision-making must incorporate the need for expedient treatment of the patient's malignancy. Some drugs will need to be avoided while dose reduction may be appropriate for other agents in patients with significant liver disease, regardless of its etiology  (<a class="graphic graphic_table graphicRef69104" href="/d/graphic/69104.html" rel="external">table 2</a>).</p><p>Infection with hepatitis B (HBV) or hepatitis C (HCV) is a common disorder that can be exacerbated or reactivated with cytotoxic chemotherapy. Importantly, many people are unaware that they have a viral infection at the time of the diagnosis of cancer [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H9"><span class="h3">Hepatitis B</span><span class="headingEndMark"> — </span>HBV infection with a high viral load prior to treatment is an adverse factor for survival and may be associated with a higher incidence of severe hepatitis during chemotherapy [<a href="#rid31">31</a>]. In addition, multiple reports have documented a significantly increased incidence of HBV reactivation in patients receiving certain types of myelosuppressive systemic chemotherapy, notably anti-CD20 therapies (ie, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9523" href="/d/drug information/9523.html" rel="external">ofatumumab</a>, and <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a>). Patients who are at high risk for HBV reactivation during chemotherapy with high-risk regimens such as these may benefit from prophylactic antiviral therapy. (See  <a class="medical medical_review" href="/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy", section on 'Very high risk'</a> and  <a class="medical medical_review" href="/d/html/128144.html" rel="external">"Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Molecularly targeted agents", section on 'Anti-CD-20 therapies and HBV reactivation'</a>.)</p><p>The magnitude of risk for less myelosuppressive chemotherapy regimens, as are used for treatment of solid tumors, has not been well established [<a href="#rid32">32,33</a>]. In a systematic review of 26 observational studies and randomized trials in patients with chronic or resolved HBV receiving chemotherapy for solid tumors, the risk of reactivation for patients with chronic HBV (ie, hepatitis B surface antigen [HBsAg] positive) ranged from 4 to 68 percent, with most studies reporting a reactivation risk greater than 10 percent [<a href="#rid32">32</a>]. For individuals with resolved HBV infection (defined as HBsAg negative, hepatitis B core antibody [anti-HBc] positive, HBV DNA negative), reactivation rates ranged from 0.3 to 9.0 percent. Antiviral therapy administered during chemotherapy reduced the risk of HBV reactivation by approximately 90 percent, and also reduced HBV-related hepatitis and the need for chemotherapy interruption. (See  <a class="medical medical_review" href="/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy", section on 'Who is at risk for HBV reactivation'</a>.)</p><p class="headingAnchor" id="H3094113182"><span class="h4">HBV screening and management</span><span class="headingEndMark"> — </span>We agree with an updated year 2020 provisional clinical opinion from the American Society of Clinical Oncology, which endorses universal HBV screening for all patients beginning systemic anticancer therapy (cytotoxic chemotherapy, immunotherapy, molecularly targeted therapy) using three tests, hepatitis B surface antigen (HbSAg), hepatitis B core antibody (anti-HBc), total immunoglobulin (Ig) or IgG, and antibody to hepatitis B surface antigen (anti-HBs) [<a href="#rid34">34</a>]. The finding of chronic HBV (HbSAg-positive) or past HBV (HbSAg-negative and anti-HBc-positive) infection requires HBV reactivation risk assessment to determine the need for antiviral prophylaxis. Their recommended approach to HBV screening, monitoring, and antiviral prophylaxis, which is largely aligned with that of the American Association for the Study of Liver Disease (AASLD), is outlined in the algorithm  (<a class="graphic graphic_algorithm graphicRef129226" href="/d/graphic/129226.html" rel="external">algorithm 1</a>). Guidelines for risk stratification are also available from the American Gastroenterology Association (AGA) [<a href="#rid35">35</a>]. The AGA and the American Society of Clinical Oncology (ASCO)/AASLD guidelines differ regarding the level of risk for certain patients, in particular those who are HBsAg negative.</p><p>This position from ASCO reflects a change in the approach that was endorsed in 2015 (which recommended HBV screening of patients receiving chemotherapy only if they were at high risk for HBV infection or if highly immunosuppressive therapy was being used [eg, hematopoietic cell transplantation or use of an anti-CD20 agent such as <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9523" href="/d/drug information/9523.html" rel="external">ofatumumab</a>, or <a class="drug drug_general" data-topicid="91388" href="/d/drug information/91388.html" rel="external">obinutuzumab</a>]) [<a href="#rid36">36</a>], and is now concordant with recommendations from other groups, including the AASLD [<a href="#rid37">37</a>]. The change in recommendation was attributed to the publication of at least three large prospective cohort studies that provide strong, albeit indirect, evidence in support of universal HBV screening in patients receiving systemic therapy for cancer because of the risk of HBV reactivation, the fact that many individuals with newly diagnosed cancer and concurrent HBV have no identifiable risk factors for infection, and the greater efficiency of universal as opposed to risk-based screening [<a href="#rid30">30,38,39</a>]. A later update from the expert panel convened by ASCO provides strategies for practical implementation of universal screening in cancer centers and community-based clinics [<a href="#rid40">40</a>]. This subject is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy"</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Hepatitis C</span><span class="headingEndMark"> — </span>Clinicians should also consider testing for chronic hepatitis C virus infection prior to initiating potentially immunosuppressive chemotherapy, although the data are less compelling than for HBV testing. Patients with chronic HCV infection who are receiving chemotherapy should undergo serial monitoring of LFTs, and if there is no dramatic change, continued chemotherapy treatment without dose modification is appropriate. (See  <a class="medical medical_review" href="/d/html/89950.html" rel="external">"Screening and diagnosis of chronic hepatitis C virus infection"</a>.) </p><p>Severe hepatitis from reactivation of HCV infection has been documented in case reports [<a href="#rid41">41-43</a>], but it seems to be less common than HBV reactivation [<a href="#rid44">44</a>], and the relationship between immunosuppressive chemotherapy and viral reactivation is less clear than for HBV.</p><p>In three large series of patients who had anti-HCV antibodies, treatment for hematologic malignancies was associated with mild LFT abnormalities in 18 percent or fewer [<a href="#rid45">45-47</a>]. In another report of 33 patients, 32 of whom had chronic disease as manifested by positivity for HCV RNA, transaminases increased in 55 percent; however, only one patient had a severe flare of underlying hepatitis [<a href="#rid48">48</a>]. Thus, although chemotherapy may be associated with elevations in LFTs in patients with HCV, this does not appear to be a major issue except for those with preexisting decompensated liver disease.</p><p>Infection with HCV does appear to increase the risk of developing SOS in patients undergoing high dose chemotherapy and hematopoietic stem cell transplantation. (See  <a class="medical medical_review" href="/d/html/129806.html" rel="external">"Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults", section on 'Risk factors'</a>.)</p><p class="headingAnchor" id="H2803484160"><span class="h3">Dose reduction for patients with baseline hepatic impairment</span><span class="headingEndMark"> — </span>Altered drug metabolism due to hepatic dysfunction can result in higher levels of systemic toxicity due to higher or more persistent drug levels. Knowledge of the pharmacokinetics of antineoplastic agents in patients with liver disease is incomplete and has generally been derived from small numbers of heterogeneous patients with only mild to moderate liver dysfunction. As a result, guidelines for dose adjustment in the setting of preexisting hepatic impairment are largely empirical  (<a class="graphic graphic_table graphicRef69104" href="/d/graphic/69104.html" rel="external">table 2</a>).</p><p>Dose adjustments must be viewed in the appropriate clinical context. Patients with metastatic disease are rarely cured, and initial chemotherapy doses that could lead to excessive treatment-related toxicity should be avoided. On the other hand, if liver function tests (LFTs) are abnormal because of extensive liver metastases, and the hepatic metastases respond to treatment, doses can often be increased after the initial courses of therapy.</p><p class="headingAnchor" id="H3742425250"><span class="h2">LiverTox</span><span class="headingEndMark"> — </span>Additional information on chemotherapy-induced liver injury is available from the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK547852%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4try0%2B5669jWuE9Ds1a1khkWX5vkEjVCKubKK5acgUH7v%2Fw%3D%3D&amp;TOPIC_ID=2837" target="_blank">LiverTox</a>, a collaborative effort of the Liver Disease Research Branch of the National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) and the National Library of Medicine (NLM). <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK547852%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4try0%2B5669jWuE9Ds1a1khkWX5vkEjVCKubKK5acgUH7v%2Fw%3D%3D&amp;TOPIC_ID=2837" target="_blank">LiverTox</a> is a freely accessible website that provides continuously updated comprehensive and evidence-based information about the clinical features of liver injury from drugs, dietary supplements, and herbal products along with a complete and annotated list of references.</p><p class="headingAnchor" id="H11"><span class="h1">SPECIFIC CYTOTOXIC AGENTS</span><span class="headingEndMark"> — </span>In the following sections, both the hepatotoxicity of specific chemotherapy agents, and recommended dose modifications for patients with preexisting hepatic impairment are discussed. An important point is that most of these agents are used in combination regimens rather than as monotherapy.</p><p>Considerations for possibly greater hepatotoxicity using specific combination regimens and the potential difficulty with establishing which agent is responsible for the hepatotoxicity are outlined below. (See <a class="local">'Combination chemotherapy regimens'</a> below.)</p><p class="headingAnchor" id="H12"><span class="h2">Alkylating agents</span><span class="headingEndMark"> — </span>As a group, alkylating agents are uncommonly associated with hepatotoxicity. Although the mechanism of liver damage associated with these agents is unclear, depletion of glutathione and oxidative injury have been implicated [<a href="#rid49">49</a>]. With the possible exception of <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, patients receiving alkylating agents usually do not require dose reduction because of underlying liver disease.</p><p class="headingAnchor" id="H13"><span class="h3">Cyclophosphamide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">Cyclophosphamide</a> is metabolized by the liver to 4-hydroxycyclophosphamide, which is in equilibrium with its acyclic tautomeric form, aldophosphamide. In susceptible cells, nonenzymatic cleavage of aldophosphamide yields phosphoramide mustard and acrolein, which are thought to be the cytotoxic metabolites.</p><p>Despite its conversion in the liver to an active metabolite, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> is infrequently hepatotoxic. Abnormal LFTs attributed to the drug have only been reported occasionally, and this effect is probably due to an idiosyncratic reaction rather than direct toxicity [<a href="#rid50">50-54</a>].</p><p>In patients undergoing treatment for vasculitis, <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> has been associated with liver necrosis when its administration was preceded by <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> (AZ) [<a href="#rid55">55</a>]. In two of the four affected patients, cyclophosphamide had previously been administered as a single agent without hepatic injury, suggesting that an interaction between the drugs was responsible for this toxicity. (See  <a class="medical medical_review" href="/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases"</a>.)</p><p>Increased toxicity has not been reported in patients with hepatic dysfunction [<a href="#rid56">56,57</a>]. Nevertheless, some clinicians recommend a 25 percent dose reduction in dose for patients with a serum bilirubin 3.1 to 5 mg/dL or aspartate transaminase (AST) greater than three times the upper limit of normal (ULN), and not giving the drug if the bilirubin is ≥5 mg/dL [<a href="#rid58">58</a>]. Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States Prescribing Information.</p><p class="headingAnchor" id="H14"><span class="h3">Ifosfamide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">Ifosfamide</a> has been uncommonly associated with hepatotoxicity; in a total of 2070 patients from 30 studies of single-agent ifosfamide, the reported incidence of liver dysfunction was 3 percent [<a href="#rid59">59,60</a>].</p><p>Dose reductions are probably not necessary for patients with altered liver function. However, <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a> is extensively hepatically metabolized, and some clinicians recommend a 75 percent dose reduction (ie, 25 percent of goal dose administered) for patients with significant hepatic dysfunction (serum AST &gt;300 int. unit/L or bilirubin &gt;3 mg/dL) [<a href="#rid58">58,61</a>]. Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States Prescribing Information.</p><p class="headingAnchor" id="H2063200564"><span class="h3">Lurbinectedin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="128469" href="/d/drug information/128469.html" rel="external">Lurbinectedin</a> is an alkylating agent that is approved for refractory small cell lung cancer. Across clinical studies, approximately two-thirds of treated patients have some elevation in ALT, which are grade 3 or 4 in 6 percent; elevations in AST are reported in about one-fourth, and are grade 3 to 4 in about 4 percent of patients [<a href="#rid62">62</a>]. The United States Prescribing Information recommends monitoring LFTs prior to initiating treatment, periodically during treatment, and has specific guidelines for withholding or reducing the dose or permanently discontinuing based on severity.</p><p class="headingAnchor" id="H1743491205"><span class="h3">Temozolomide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9699" href="/d/drug information/9699.html" rel="external">Temozolomide</a> is an orally active alkylating agent used predominantly for the treatment of adults with primary brain tumors. Patients with mild to moderate hepatic dysfunction have similar pharmacokinetics compared to those with normal function, although patients with severe hepatic dysfunction have not been studied [<a href="#rid63">63</a>].</p><p>Fatal and severe hepatotoxicity has been reported in patients receiving <a class="drug drug_general" data-topicid="9699" href="/d/drug information/9699.html" rel="external">temozolomide</a> [<a href="#rid64">64-67</a>]. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D6c8529ec-8936-4fec-a1a5-2b285c7e4859&amp;token=Ng3qqecFSE7TdUfoHvTos6d%2BTm44s16ACQdhgyJeR%2BOzqElEEQFau8yfO4TqlQDNLHUYjaACVMFTYY1YIk2comxW7%2BvygaHE1fK3pA5WcmK%2BXEWYdxk9H9MME0WpDdRj&amp;TOPIC_ID=2837" target="_blank">United States Prescribing Information</a> for temozolomide recommends that LFTs be performed at baseline, midway through the first cycle, prior to each subsequent cycle, and approximately two to four weeks after the last dose of temozolomide.</p><p class="headingAnchor" id="H15"><span class="h3">Other alkylating agents</span><span class="headingEndMark"> — </span>Other alkylating agents generally are not dependent upon the liver for the metabolism and are not frequently associated with hepatotoxicity.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Melphalan</strong> – <a class="drug drug_general" data-topicid="9605" href="/d/drug information/9605.html" rel="external">Melphalan</a> is rapidly hydrolyzed in plasma, and approximately 15 percent is excreted unchanged in the urine; the remainder is metabolized and excreted in stool. Although melphalan is not associated with hepatotoxicity at usual oral doses, transient LFT abnormalities have been reported with the higher doses used in the setting of hematopoietic stem cell transplantation [<a href="#rid68">68,69</a>]. (See  <a class="medical medical_review" href="/d/html/3557.html" rel="external">"Preparative regimens for hematopoietic cell transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chlorambucil</strong> – <a class="drug drug_general" data-topicid="9240" href="/d/drug information/9240.html" rel="external">Chlorambucil</a> rarely causes hepatotoxicity [<a href="#rid70">70,71</a>]. In one autopsy series of 181 patients with hematologic malignancies, three of six cases of cholestatic jaundice were attributed to chlorambucil [<a href="#rid70">70</a>]. In a second case report, drug-induced hepatotoxicity and skin rash recurred upon rechallenge with chlorambucil [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Busulfan</strong> – <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">Busulfan</a> is rapidly cleared from the blood after intravenous administration and almost entirely excreted in the urine as methanesulfonic acid; hepatic metabolism is unimportant. At standard doses, busulfan rarely causes hepatic dysfunction, although it has been linked to some cases of cholestatic hepatitis [<a href="#rid72">72,73</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">Busulfan</a> is a common component of preparative regimens for hematopoietic cell transplantation. In this setting, busulfan has been associated with hepatic sinusoidal obstruction syndrome (SOS). (See <a class="local">'Hepatic vascular injury'</a> above and  <a class="medical medical_review" href="/d/html/129806.html" rel="external">"Hepatic sinusoidal obstruction syndrome (veno-occlusive disease) in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bendamustine</strong> – <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">Bendamustine</a> undergoes hepatic metabolism, and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D864f1c02-761f-4049-89fa-7aeec4118226&amp;token=XLW2KUxyjPCpr4PzTR1pekc5L3VMcNPKCR0cvGb%2FWx0tL2LmETKQmYPPjs4hSwMKhqsciDQiIZugOY8RhMyOGc46cBbXXr9Em4hidpIWGPDsC0AnhAl5JNK%2BPardts5C&amp;TOPIC_ID=2837" target="_blank">United States Prescribing Information</a> for bendamustine recommends that the drug not be administered to patients with preexisting moderate to severe hepatic impairment (transaminases ≥2.5 times ULN or total bilirubin ≥1.5 times ULN).</p><p></p><p class="headingAnchor" id="H16"><span class="h2">Nitrosoureas</span><span class="headingEndMark"> — </span>The nitrosoureas <a class="drug drug_general" data-topicid="9206" href="/d/drug information/9206.html" rel="external">carmustine</a> (BCNU), <a class="drug drug_general" data-topicid="9569" href="/d/drug information/9569.html" rel="external">lomustine</a> (CCNU), and <a class="drug drug_general" data-topicid="9949" href="/d/drug information/9949.html" rel="external">streptozocin</a> appear to function as both alkylating and carbamoylating agents. Like other alkylating agents, nitrosoureas deplete hepatic stores of glutathione [<a href="#rid74">74</a>], which may increase the risk of oxidative injury.</p><p>Increases in LFTs occur in 20 to 25 percent of carmustine-treated patients [<a href="#rid75">75,76</a>], and the onset may be delayed up to four months following treatment. At conventional doses, LFT elevations are usually mild and revert to normal over a brief period, although fatalities have been reported. The hepatotoxic effects of CCNU are similar [<a href="#rid77">77</a>].</p><p>Streptozocin-induced hepatotoxicity is manifest primarily as hepatocellular injury and has been reported in 15 to 67 percent of treated patients [<a href="#rid78">78,79</a>]. These changes appear within a few days to weeks after treatment and are usually asymptomatic; rapid, complete resolution is the rule.</p><p>Although dosing adjustment may be necessary in patients with severe hepatic dysfunction, no guidelines have been published for any of the nitrosoureas. Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States Prescribing Information. Hepatic function should be closely monitored during treatment.</p><p class="headingAnchor" id="H17"><span class="h2">Antimetabolites</span><span class="headingEndMark"> — </span>The hepatotoxic potential of antimetabolites is variable. Hepatic metabolism plays an important role in the disposition of many drugs in this class, and dose reduction is frequently necessary in patients with liver dysfunction.</p><p class="headingAnchor" id="H18"><span class="h3">Cytarabine</span><span class="headingEndMark"> — </span>Hepatotoxicity from <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> has been difficult to establish because it is used for treatment of leukemia, and these patients frequently undergo transfusions of blood products, are subject to infections, receive multiple medications, and are often not candidates for liver biopsy because of prolonged thrombocytopenia. Abnormal LFTs were reported in 37 of 85 leukemic patients receiving cytarabine in an early series, but many patients had preexisting LFT abnormalities, potentially confounding factors (eg, sepsis or hemolysis), or spontaneous resolution of biochemical abnormalities despite continuation of therapy [<a href="#rid80">80</a>].</p><p>In more contemporary reports, <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> infrequently causes histologically proven cholestasis [<a href="#rid81">81,82</a>]. Furthermore, transiently abnormal LFTs developed in 24 of 27 patients undergoing high-dose cytarabine by 72-hour continuous infusion in one series [<a href="#rid83">83</a>]. These effects are reversible and generally not dose-limiting [<a href="#rid83">83-85</a>].</p><p>The liver is the primary site for the detoxification of much of the administered dose of <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>. Doses should be reduced in patients with severe hepatic dysfunction in order to avoid an increased risk of treatment-related central nervous system toxicity [<a href="#rid86">86</a>]. (See  <a class="medical medical_review" href="/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Cytarabine'</a>.)</p><p>Some clinicians recommend a 50 percent decrease in the dose in patients with any aminotransferase elevation [<a href="#rid58">58</a>]. However, this is not routinely done in potentially curative settings such as induction therapy for acute myelogenous leukemia. Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States Prescribing Information.</p><p class="headingAnchor" id="H19"><span class="h3">Fluorouracil and capecitabine</span><span class="headingEndMark"> — </span>Following intravenous administration, approximately 10 percent of administered <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> (FU) is excreted unchanged in the urine, while the remainder is catabolized by dihydropyrimidine dehydrogenase (DPD), primarily in the liver. Both the toxicity and the antitumor effect are potentiated if catabolism is blocked by inhibition or inactivity of DPD. (See  <a class="medical medical_review" href="/d/html/2824.html" rel="external">"Chemotherapy-associated diarrhea, constipation and intestinal perforation: pathogenesis, risk factors, and clinical presentation"</a>.)</p><p>Only rare reports of hepatotoxicity have been noted with FU [<a href="#rid87">87</a>]. More hepatotoxicity has been reported when FU is administered in combination with <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> and/or <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>. (See <a class="local">'Hepatic vascular injury'</a> above.)</p><p><a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">Capecitabine</a> is a fluoropyrimidine that is absorbed through the intestinal wall and then metabolized to the active metabolite, FU. Capecitabine causes hyperbilirubinemia, but this is sometimes attributable to hemolysis [<a href="#rid88">88-90</a>].</p><p>Because of the liver's role in the catabolism of intravenous FU, some clinicians recommend that doses be omitted in patients with liver failure (serum bilirubin &gt;5 mg/dL)  (<a class="graphic graphic_table graphicRef69104" href="/d/graphic/69104.html" rel="external">table 2</a>) [<a href="#rid58">58</a>]. Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States Prescribing Information. By contrast, the pharmacology of <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> does not appear to be significantly affected by liver dysfunction [<a href="#rid91">91</a>], and dose reduction is not recommended in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2022%2F020896s044s045s046s047s048s049s050s051lbl.pdf&amp;token=4B0K5rF5yu1uo2TlDbIzJrQXhEUgCGp2mWQzOLmO1W2oqzDAkG5qF3mBYqFrqQMbnDUnup18v%2FwG3cN9UFHxZ7wSSA9OytpIobUIkmfhXbl66EFuz4ZQlRZZmA%2FKT4vY&amp;TOPIC_ID=2837" target="_blank">United States Prescribing Information for capecitabine</a>, although such patients should be monitored more frequently for adverse reactions.</p><p class="headingAnchor" id="H20"><span class="h3">Floxuridine</span><span class="headingEndMark"> — </span>The FU metabolite <a class="drug drug_general" data-topicid="8942" href="/d/drug information/8942.html" rel="external">floxuridine</a> (fluorodeoxyuridine [FUdR]) is administered via the hepatic artery, usually for patients with isolated liver metastases from colorectal carcinoma. (See  <a class="medical medical_review" href="/d/html/2515.html" rel="external">"Nonsurgical local treatment strategies for colorectal cancer liver metastases", section on 'Hepatic intra-arterial chemotherapy'</a>.)</p><p>Intraarterial FUdR is associated with significant dose-limiting liver toxicity. Hepatic damage can be manifested in two ways [<a href="#rid92">92-94</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatocellular injury with increased AST/alanine aminotransferase (ALT), alkaline phosphatase, and serum bilirubin (hepatitis pattern).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biliary sclerosis, which results either from toxic effects on the biliary system or ischemic changes secondary to fibrosis of the pericholangitic venous plexus, both of which can result in stricture of the bile ducts [<a href="#rid95">95-100</a>]. The incidence ranges from 1 to 26 percent. Stricture of the intrahepatic or extrahepatic bile ducts is accompanied by elevated alkaline phosphatase and serum bilirubin.</p><p></p><p>FUdR-related hepatotoxicity appears to be both time and dose dependent. With rare exception, the hepatitis pattern improves with the temporary cessation of chemotherapy; however, secondary biliary sclerosis is irreversible (although treatable with stenting or dilatation) [<a href="#rid101">101,102</a>]. Two patterns of sclerosis may be evident: a diffuse pattern or a diffuse pattern with short segments of tight stricture, which are usually located in the proximal bile ducts.</p><p>LFTs should be checked at least weekly during therapy with intrahepatic arterial FUdR and drug administration discontinued (ie, the pump emptied) when hepatic toxicity becomes evident. Treatment should be restarted only when toxicity has resolved. Dose adjustment guidelines for FUdR in this setting have been published  (<a class="graphic graphic_table graphicRef67680" href="/d/graphic/67680.html" rel="external">table 3</a>) [<a href="#rid103">103</a>]. Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States Prescribing Information.</p><p class="headingAnchor" id="H21"><span class="h3">Gemcitabine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">Gemcitabine</a> is commonly associated with a transient rise in serum aminotransferases [<a href="#rid104">104</a>], but these are seldom of clinical significance; liver failure and death are very rare. There are case reports of rare fatal cholestatic hepatotoxicity [<a href="#rid105">105</a>].</p><p>There are limited and conflicting data about <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> dosing in patients with preexisting liver dysfunction:</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective study of 18 patients with preexisting liver dysfunction who were enrolled into a phase I trial of escalating <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> doses, giving gemcitabine to patients with preexisting hyperbilirubinemia (bilirubin levels &gt;1.6 mg/dL) led to further deterioration in liver function [<a href="#rid106">106</a>]. The authors recommended an empiric initial dose reduction to 800 rather than 1000 mg/m<sup>2</sup> in this setting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On the other hand, a case series of seven patients who received at least one dose of <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> (1000 mg/m<sup>2</sup>) when their serum bilirubin level was ≥4.5 mg/dL suggests that the full dose of gemcitabine can be given safely in patients with severe hepatic dysfunction [<a href="#rid107">107</a>]. Only one patient had a platelet count below 100,000 cells/microL that warranted reduction or withholding of a dose, and no patient had a further deterioration of liver function.</p><p></p><p class="bulletIndent1">Similarly, a review of 29 patients receiving combined <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus nanoparticle albumin-bound <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> (<a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">nabpaclitaxel</a>) for advanced pancreatic cancer (predominantly at full dose) who had an elevated bilirubin level did not reveal unexpected hematologic or hepatic toxicities, even among those with an initial total bilirubin level &gt;5 mg/dL [<a href="#rid108">108</a>].</p><p></p><p>Specific dosing guidelines for patients with hepatic insufficiency are not provided in the United States Prescribing Information. However, it is probably prudent to utilize at least a 20 percent dose reduction for patients with hyperbilirubinemia of grade 2 or worse (&gt;1.5 times ULN)  (<a class="graphic graphic_table graphicRef77533" href="/d/graphic/77533.html" rel="external">table 1</a>) [<a href="#rid109">109</a>]. In the absence of toxicity, dose re-escalation could be considered.</p><p class="headingAnchor" id="H22"><span class="h3">Mercaptopurine</span><span class="headingEndMark"> — </span>Hepatotoxicity related to the purine analog <a class="drug drug_general" data-topicid="9612" href="/d/drug information/9612.html" rel="external">6-mercaptopurine</a> (6-MP) is most common if the usual daily dose of 2 mg/kg is exceeded. Two patterns have been noted: cholestatic liver damage and hepatocellular injury [<a href="#rid110">110-114</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with cholestasis, histologic features include bland cholestasis, with minimal hepatic necrosis but significant cytologic atypia and disorganized hepatic cords [<a href="#rid113">113,114</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatocellular injury typically occurs more than 30 days after treatment initiation. Moderate elevations in serum transaminases and alkaline phosphatase are accompanied by serum bilirubin levels between 3 and 7 mg/dL [<a href="#rid111">111</a>].</p><p></p><p>Changing the route of administration from oral to intravenous does not alter the pattern of hepatotoxicity [<a href="#rid115">115</a>]. Spontaneous resolution generally follows drug discontinuation.</p><p>Hepatotoxicity is thought to be a direct toxic effect of 6-MP because rechallenge does not necessarily shorten the latent period, and systemic manifestations of hypersensitivity (eg, rash, arthralgias, and eosinophilia) are usually not present [<a href="#rid111">111</a>]. However, in a series of 396 patients treated with 6-MP (1.5 mg/kg per day for an average of 60 months) for refractory inflammatory bowel disease, hepatitis developed in only one, and liver biopsy suggested a hypersensitivity reaction [<a href="#rid116">116</a>]. </p><p>Severe and potentially fatal hepatotoxicity has also been described in patients treated with the combination of standard dose 6-MP and <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>. (See <a class="local">'Combination chemotherapy regimens'</a> below.) </p><p>6-MP is metabolized in the liver by xanthine oxidase. Although specific guidelines are not available, dose reduction should be considered in patients with severe liver dysfunction to prevent drug accumulation.</p><p class="headingAnchor" id="H23"><span class="h3">Azathioprine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">Azathioprine</a> (AZ), a nitroimidazole derivative of 6-MP, is used as an immunosuppressive agent [<a href="#rid117">117</a>].</p><p>Hepatotoxicity is less frequent, milder, and less dose-dependent compared with 6-MP. Three different patterns of hepatotoxicity have been reported: hypersensitivity, an idiosyncratic cholestatic reaction, and presumed endothelial cell injury, with raised portal pressures, SOS, or peliosis hepatis [<a href="#rid118">118</a>]. Most reports of SOS have been observed in the setting of renal or hepatic transplantation. (See  <a class="medical medical_review" href="/d/html/3571.html" rel="external">"Drug-induced liver injury"</a> and <a class="local">'Hepatic vascular injury'</a> above.)</p><p>Cholestatic injury is characterized by an increased serum bilirubin and alkaline phosphatase, with moderate elevations in AST/ALT, and by variable degrees of parenchymal cell necrosis [<a href="#rid118">118-120</a>]. It is speculated that patients who develop hepatotoxicity convert AZ into 6-MP at an unusually rapid rate [<a href="#rid121">121</a>], an example of genetically-determined host metabolic idiosyncrasy.</p><p class="headingAnchor" id="H24"><span class="h3">Thioguanine</span><span class="headingEndMark"> — </span>6-thioguanine (6-TG) has been implicated in the development of hepatic SOS [<a href="#rid14">14,122-124</a>] and in a single case of peliosis hepatis [<a href="#rid125">125</a>]. An early report described jaundice among the potential adverse reactions [<a href="#rid126">126</a>]. 6-TG is rapidly and extensively metabolized in the liver. Thus, dose reduction or avoidance is recommended in patients with hepatic disease, although formal guidelines are lacking. (See <a class="local">'Hepatic vascular injury'</a> above.)</p><p class="headingAnchor" id="H25"><span class="h3">Methotrexate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> (MTX) is a frequent component of combination chemotherapy regimens and is also used to treat a variety of nonmalignant disorders.</p><p>MTX-induced hepatotoxicity in patients receiving the drug parenterally for treatment of cancer usually takes the form of an acute transaminitis. This is most common in patients receiving high-dose MTX, which causes acute transaminitis in as many as 60 to 80 percent of patients; levels typically return to baseline within one to two weeks. (See  <a class="medical medical_review" href="/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate", section on 'Hepatotoxicity'</a>.)</p><p>In contrast, patients undergoing chronic low-dose MTX therapy for rheumatoid arthritis or psoriasis are at risk for cirrhosis and fibrosis. This topic is discussed separately. (See  <a class="medical medical_review" href="/d/html/7508.html" rel="external">"Hepatotoxicity associated with chronic low-dose methotrexate for nonmalignant disease"</a>.)</p><p>There are at least three case reports of hepatocellular carcinoma developing in patients with MTX-induced hepatic fibrosis, all of which were in children treated for acute lymphocytic leukemia (ALL), one in a patient heterozygous for alpha-1 antitrypsin deficiency [<a href="#rid127">127-129</a>]. These data suggest a potential for long-term carcinogenesis following treatment with MTX, at least in the rare patient who develops hepatic fibrosis. (See  <a class="medical medical_review" href="/d/html/1429.html" rel="external">"Extrapulmonary manifestations of alpha-1 antitrypsin deficiency"</a>.)</p><p>In low doses, MTX is excreted mainly unchanged in the urine, while in high doses (such as are used to treat osteosarcoma and central nervous system [CNS] lymphoma), it is partially metabolized by the liver to 7-hydroxymethotrexate [<a href="#rid130">130</a>]. Specific dosing guidelines for hepatic insufficiency are not available in the United States Prescribing Information. Some clinicians suggest a 25 percent dose reduction for patients with either serum bilirubin 3.1 to 5 mg/dL or aminotransferases &gt;3 times ULN, and omission of the drug for higher bilirubin levels [<a href="#rid58">58</a>]. Guidelines from <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cancercareontario.ca%2Fen%2Fcancer-treatments%2Fchemotherapy%2Fdrug-formulary&amp;token=4okUGOifULgrOM%2FOf6s%2Bxljpd%2BBmMbQBfS%2BMcjv4RezeZouIU2k%2Fi9Qt9XYstnyrAhGOPYvfBUgLWG2hNOeq9457DjpfOYym8JB9Lg38feA%3D&amp;TOPIC_ID=2837" target="_blank">Cancer Care Ontario</a> recommend not using the drug if the total bilirubin level is &gt;4 times ULN.</p><p>Any third-space fluid (eg, ascites, pleural effusions) will accumulate MTX and act as a reservoir for slow distribution into the plasma, increasing the risk of toxicity [<a href="#rid131">131</a>]. Large pleural or peritoneal effusions should be drained prior to therapy (particularly with high-dose MTX), and if this not possible, dose reduction is appropriate. (See  <a class="medical medical_review" href="/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate"</a>.)</p><p class="headingAnchor" id="H10245190"><span class="h3">Pemetrexed and pralatrexate</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">Pemetrexed</a> and <a class="drug drug_general" data-topicid="9530" href="/d/drug information/9530.html" rel="external">pralatrexate</a> are novel folate analogs used in the treatment of lung cancer and refractory T-cell lymphomas, respectively. There are no published guidelines to guide dose reductions for patients with preexisting hepatic dysfunction. However, both drugs are potentially hepatotoxic, and guidelines for dose reduction for patients who develop grade 3 or 4 treatment-related hepatotoxicity during treatment are available in the United States Prescribing Information:</p><p class="bulletIndent1"><span class="glyph">●</span>For <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D46a9b89d-7135-4e0c-b8e4-52580554769b&amp;token=Ey3X0hBlfPsvqiq2X%2B7ve2gAekRs24BGnVsG4AW3p5Wpz8ENwvlLwun1Md2r9VhfNX7lGWRTZ4R9HP2xT4hmuE3qNimkn4Bk3GAogAv6rcaboRNPOFK6q9wI5wjyOux7&amp;TOPIC_ID=2837" target="_blank">pemetrexed</a>, reduce dose by 75 percent for bilirubin elevation &gt;3 times ULN or transaminase elevation &gt;5 times ULN.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D9f3d9c4d-9386-4451-b712-0fbdc5478d8f&amp;token=Wtoi49qN9ETrHjgJnUFWYGm2c80seHr5j6Gnn%2BrqNMq5XQX1h%2B8XjPXpUzX%2BloA1BCrWRVJQQ7oaRpV2a3ZXW1vdqt1ZLM5lyRYo0ycig8qapK9cyINgYhBObMxPWdnv&amp;TOPIC_ID=2837" target="_blank">pralatrexate</a>, if total bilirubin &gt;3 to 10 times ULN, or transaminases &gt;5 to 20 times ULN, omit dose; after recovery to ≤grade 2 toxicity, decrease dose to 20 mg/m<sup>2</sup>. For bilirubin &gt;10 times ULN or transaminases &gt;20 times ULN, discontinue treatment.</p><p></p><p class="headingAnchor" id="H26"><span class="h2">Antitumor antibiotics</span></p><p class="headingAnchor" id="H27"><span class="h3">Anthracyclines</span><span class="headingEndMark"> — </span>The anthracyclines include <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> (free and liposome-encapsulated), <a class="drug drug_general" data-topicid="9326" href="/d/drug information/9326.html" rel="external">daunorubicin</a> (free and liposome-encapsulated), <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a>, and <a class="drug drug_general" data-topicid="8549" href="/d/drug information/8549.html" rel="external">idarubicin</a>. Doxorubicin is the most widely studied of these agents; the other compounds appear to be metabolized similarly and have a comparable pattern of toxicity.</p><p>Isolated case reports have suggested that <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> can cause increased aminotransferases and hyperbilirubinemia [<a href="#rid132">132</a>]. However, these have generally been in the context of acute leukemia, where multiple factors may have contributed to hepatic dysfunction, or in patients undergoing right upper quadrant irradiation. (See <a class="local">'Irradiation plus chemotherapy'</a> above.)</p><p><a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">Doxorubicin</a> is extensively metabolized in the liver; approximately 80 percent of each dose is excreted in bile. Patients with cholestasis have delayed clearance of doxorubicin and its metabolites and greater systemic toxicity [<a href="#rid133">133-135</a>]. In contrast, patients with cirrhosis or isolated aminotransferase elevation may have normal drug clearance; excess toxicity has been reported from standard doses in some [<a href="#rid136">136,137</a>], but not all [<a href="#rid138">138</a>], studies.</p><p>Approaches to <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> dosing in patients with impaired liver function are variable  (<a class="graphic graphic_table graphicRef69104" href="/d/graphic/69104.html" rel="external">table 2</a>) [<a href="#rid58">58,86,138-140</a>]. The United States Prescribing Information for <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3De0349f98-42fa-4003-b6d8-a1db1401b0ef&amp;token=avf9Wm%2BjxB29bH22rBUi1lrUJ6v6TzTJVJmj%2FJeg1uIOQTcuEh6b83elmR04NOihnNyoCON%2BoOvNjJUzBOm4VMtqqU3jQHKw4giKT1Xo%2FrCk0NbHaKz8KRWPI6CXAbj%2B&amp;TOPIC_ID=2837" target="_blank">doxorubicin</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Dce69f195-76fc-4c95-869e-14ea9a076655&amp;token=J1O8ixBturu6T%2BXfBwzYw%2Ff7xBITR4MRFuMa4TpAVJkaj%2BNJOO7D6gZyqbH1%2B%2BKKq6sSZqINrWuKuXhBclnPa%2FpaxDq4euMk6n53TiFwCcYFHGA3sTDFjFZucSqLIf2c&amp;TOPIC_ID=2837" target="_blank">pegylated liposomal doxorubicin</a> recommend a 50 percent dose reduction for bilirubin 1.2 to 3 mg/dL, and a 75 percent dose reduction for bilirubin 3.1 to 5 mg/dL. Others suggest omission of the drug for bilirubin &gt;5 mg/dL [<a href="#rid58">58,109</a>].</p><p>The applicability of these guidelines to weekly schedules of <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> administration is uncertain. In one report, weekly administration was well tolerated in a woman with hepatic metastases from breast cancer and hyperbilirubinemia; treatment led to symptomatic improvement and normalization of LFTs [<a href="#rid141">141</a>].</p><p>The United States Prescribing Information for <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Df7ec5ec1-fb05-4c78-b821-9aea638cf144&amp;token=MOEjGLT4YLewkfvr9wKUqpt5%2BCbesp%2BbxLQY5QJCakESvTBaMFMZzWNdMkZwSectuKgYS1KCxpT4bIYjFIDCfKOek0kIHFnTWSRmPxq0p%2FyY5F2x6aXdmOEcWbhD3aBk&amp;TOPIC_ID=2837" target="_blank">epirubicin</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D227784a8-ce68-4dd4-8ac5-a65265969677&amp;token=qQzpjRuMuRzM6fza1BVU%2B1lxgX4S10xWpnQcnysKLTCIvVyiIOrpRuk7Ols%2B%2F%2FswsQr5Gf7m9qCXBnMC4Nw8aeFtBsZJpRUM7FjqR1MCFOmjYAnLLDT3MD8jBq%2FmiPBx&amp;TOPIC_ID=2837" target="_blank">daunorubicin</a> also recommends dose reduction for patients with serum bilirubin levels ≥1.2 mg/dL, and for <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a>, a dose reduction for aminotransferase levels &gt;2 times ULN  (<a class="graphic graphic_table graphicRef69104" href="/d/graphic/69104.html" rel="external">table 2</a>). Others have suggested dose modification for epirubicin based upon serum AST and the desired drug exposure level, but measurement of drug levels is not a common practice [<a href="#rid142">142</a>].</p><p>Specific recommendations are not available for <a class="drug drug_general" data-topicid="8549" href="/d/drug information/8549.html" rel="external">idarubicin</a>, although the United States Prescribing Information suggests that a dose reduction be considered in patients with hepatic impairment.</p><p class="headingAnchor" id="H28"><span class="h3">Mitoxantrone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">Mitoxantrone</a> is an anthraquinone that is structurally related to the anthracyclines. In patients with leukemia, transient elevations in aminotransferase levels have been reported [<a href="#rid143">143,144</a>].</p><p>Total body drug clearance is reduced in patients with altered liver function, particularly hyperbilirubinemia [<a href="#rid145">145-147</a>]. Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States Prescribing Information. Some clinicians recommend maintaining a standard dose of 14 mg/m<sup>2</sup> for moderate dysfunction (bilirubin 1.5 to 3.5 mg/dL) and reducing the dose to 8 mg/m<sup>2 </sup>or avoidance of <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a> for those with severe hepatic impairment and a bilirubin level &gt;3.5 mg/dL [<a href="#rid145">145</a>].</p><p class="headingAnchor" id="H29"><span class="h3">Bleomycin</span><span class="headingEndMark"> — </span>Approximately one-half of each administered dose of <a class="drug drug_general" data-topicid="9160" href="/d/drug information/9160.html" rel="external">bleomycin</a> is excreted unchanged in the urine; the remainder is inactivated by an aminopeptidase that is present in many tissues, including liver. Most studies report a low incidence of liver dysfunction in patients receiving bleomycin [<a href="#rid148">148,149</a>]. One review of over 1000 treated patients concluded that hepatotoxicity was inconsistently reported, and no specific pattern could be ascribed to this drug [<a href="#rid148">148</a>].</p><p class="headingAnchor" id="H30"><span class="h3">Mitomycin</span><span class="headingEndMark"> — </span>Although hepatotoxicity is rare in patients treated with <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a>, drug-induced alterations in LFTs [<a href="#rid150">150</a>] and hepatic SOS in the setting of high-dose therapy with hematopoietic cell transplantation [<a href="#rid151">151</a>] have been reported.</p><p><a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">Mitomycin</a> is metabolized predominantly in the liver; less than 10 percent is excreted unchanged in the urine, and biliary excretion also accounts for some elimination [<a href="#rid152">152</a>]. However, there are conflicting data regarding the influence of hepatic function on mitomycin clearance. In one report of 30 patients treated with mitomycin, there was no relationship between abnormal liver function, elimination half-life, and total body clearance [<a href="#rid153">153</a>]. Others have documented increased myelotoxicity in patients with preexisting hepatic dysfunction [<a href="#rid154">154</a>].</p><p>Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States Prescribing Information. A number of different approaches have been utilized in patients with neoplasia-related hepatic dysfunction:</p><p class="bulletIndent1"><span class="glyph">●</span>In a series of women with advanced breast cancer and a predominance of visceral disease, initial <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a> doses were empirically adjusted for liver dysfunction as follows: bilirubin 1.5 to 3 mg/dL, 50 percent of dose; bilirubin &gt;3.1 mg/dL, 25 percent of dose [<a href="#rid155">155</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second report, the dose of <a class="drug drug_general" data-topicid="9658" href="/d/drug information/9658.html" rel="external">mitomycin</a> was empirically decreased by 50 percent in patients with a serum bilirubin &gt;3 mg/dL or hepatic enzymes &gt;3 times ULN [<a href="#rid156">156</a>].</p><p></p><p class="headingAnchor" id="H31"><span class="h3">Dactinomycin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9318" href="/d/drug information/9318.html" rel="external">Dactinomycin</a> can cause a transient elevation in aminotransferases, which has most commonly occurred in children who received prior radiation therapy to the right upper quadrant. In this setting, greater than anticipated leukopenia and thrombocytopenia have also occurred, suggesting prolonged drug excretion due to radiation-induced hepatotoxicity [<a href="#rid157">157</a>]. (See <a class="local">'Irradiation plus chemotherapy'</a> above.)</p><p>Hepatotoxicity also occurs in unirradiated patients receiving <a class="drug drug_general" data-topicid="9318" href="/d/drug information/9318.html" rel="external">dactinomycin</a> and appears to be schedule dependent [<a href="#rid158">158,159</a>]. In one series of patients with Wilms tumor receiving dactinomycin either on five consecutive days or a double dose on a single day, hepatotoxicity developed in 13 versus 0 percent [<a href="#rid158">158</a>].</p><p>A hepatopathy-thrombocytopenia syndrome (HTS) has been described in approximately 1 percent of children treated with <a class="drug drug_general" data-topicid="9318" href="/d/drug information/9318.html" rel="external">dactinomycin</a> for Wilms tumor [<a href="#rid11">11</a>]. Hepatic veno-occlusive disease (VOD) is also reported. (See <a class="local">'Hepatic vascular injury'</a> above.)</p><p>Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States Prescribing Information. A 50 percent reduction of dose has been recommended by some clinicians  (<a class="graphic graphic_table graphicRef69104" href="/d/graphic/69104.html" rel="external">table 2</a>) [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H32"><span class="h3">Dacarbazine</span><span class="headingEndMark"> — </span>There have been several reports of hepatic vascular toxicity in adults with melanoma who received single-agent <a class="drug drug_general" data-topicid="9316" href="/d/drug information/9316.html" rel="external">dacarbazine</a> (DTIC). Clinical findings include acute hepatic failure, shock, and death within a few days [<a href="#rid160">160</a>]. Histologically, acute thrombotic occlusions are present involving the small and medium-sized veins, unlike classic nonthrombotic SOS. Eosinophilia and eosinophilic infiltrates are frequently present, suggesting an idiosyncratic hypersensitivity mechanism rather than direct endoluminal damage [<a href="#rid5">5,160</a>]. (See <a class="local">'Hepatic vascular injury'</a> above.)</p><p>DTIC is metabolized by the hepatic microsomal pathway. Although patients with abnormal liver function may be at increased risk for hematologic toxicity [<a href="#rid86">86</a>], standard guidelines are not available for dose reduction in this setting.</p><p class="headingAnchor" id="H33"><span class="h2">Tubulin-acting agents</span><span class="headingEndMark"> — </span>Cytotoxic drugs that act upon tubulin and microtubules require dose reduction in the setting of hepatic dysfunction.</p><p class="headingAnchor" id="H34"><span class="h3">Vinca alkaloids</span><span class="headingEndMark"> — </span>Transient abnormalities in LFTs have been seen following treatment with both <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> [<a href="#rid161">161</a>] and <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a> [<a href="#rid162">162</a>]. More severe hepatotoxicity is reported in patients who received vincristine plus concurrent irradiation. (See <a class="local">'Irradiation plus chemotherapy'</a> above.)</p><p>The vinca alkaloids are metabolized primarily by the liver, and the bile is the main route of excretion. Liver dysfunction that is severe enough to raise the serum alkaline phosphatase and alter biliary excretion results in delayed clearance of <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a> and <a class="drug drug_general" data-topicid="10044" href="/d/drug information/10044.html" rel="external">vinblastine</a> with a greater potential for toxicity [<a href="#rid58">58,86,163,164</a>].</p><p>The United States Prescribing Information for both <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Db22e4c8e-dbe1-4d4b-a026-e1812974071c&amp;token=6GIqJ7gw%2BoJkSv15q44tMn%2FzfwrMWkBdZBpB22Gj9n7gehxCVYt1gwPXbx8CmVo0lcac79Cfy%2BjwtOrBgtSe1Cws9TH4Xk5iLEWgPdvqFw0oqL3gEuVgi9KvbMkX2%2FU7&amp;TOPIC_ID=2837" target="_blank">vincristine</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Df073b58e-56d6-4c8d-a2ce-b37719402d77&amp;token=omiDQ7%2FS2pEs2MSvXNK1XON%2Flt7UTcX5lW8pG%2FOMXsn%2Fl%2B0wnblYN5tu8gnlbyoG4JSrS1e2IBefZOcCKymIFROe4JGikk5kCSd5HSaj3dASwEKytm5EgW1VPyz%2FrHmm&amp;TOPIC_ID=2837" target="_blank">vinblastine</a> recommends that the dose of either agent be reduced by 50 percent in patients with a serum bilirubin &gt;3 mg/dL. Other guidelines for dosing adjustments have been recommended by some clinicians [<a href="#rid58">58,109</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum bilirubin 1.5 to 3 mg/dL or aminotransferases two to three times ULN – Administer 50 percent of normal dose</p><p class="bulletIndent1"><span class="glyph">●</span>Serum bilirubin &gt;3 mg/dL or aminotransferases &gt;3 times ULN – Omit dose</p><p></p><p>There is less information available for <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a>. The United States Prescribing Information for <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2Fsearch.cfm%3Flabeltype%3Dall%26query%3Dvinorelbine%26pagesize%3D20%26page%3D1%26audience%3Dprofessional&amp;token=%2BXPf8%2BrkiDGM3fe%2F2yTxfat8JjfTA82itLOicE1T4kp1jSoAilZd43vELs9vy9y4LR%2BO6u5Uu%2FqOJOyGX%2BQsC1wFLNTInx0MXqJYmJXTuRRfu1H%2B7sSMEL1mghjnuiz%2Fqk0sJszE9Tw3S8DHnW%2F4ZQ%3D%3D&amp;TOPIC_ID=2837" target="_blank">vinorelbine</a> recommends a 50 percent dose reduction for patients who develop moderate liver dysfunction during therapy (total bilirubin 2.1 to 3 mg/dL), and a 75 percent dose reduction for more severe hyperbilirubinemia  (<a class="graphic graphic_table graphicRef69104" href="/d/graphic/69104.html" rel="external">table 2</a>). Others suggest that dose modification may not be necessary with mild to moderate liver impairment (total bilirubin &lt;3 times ULN, transaminases &lt;2.5 times ULN) [<a href="#rid165">165,166</a>].</p><p class="headingAnchor" id="H35"><span class="h3">Etoposide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">Etoposide</a> is not usually hepatotoxic at standard doses [<a href="#rid167">167</a>], although at least one report documents severe hepatocellular injury [<a href="#rid168">168</a>]. At high doses, etoposide has been associated with hyperbilirubinemia and elevated transaminases and alkaline phosphatase levels approximately three weeks after administration [<a href="#rid169">169,170</a>]. These abnormalities cleared without sequelae over 12 weeks.</p><p><a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">Etoposide</a> is extensively (97 percent) protein bound, and 70 to 80 percent of drug is eliminated through nonrenal mechanisms, presumably liver metabolism and bile excretion. Elevated serum bilirubin levels have been correlated with decreased clearance and enhanced leukopenia in some [<a href="#rid171">171,172</a>], but not all [<a href="#rid173">173-175</a>], studies. Others suggest that patients with increased bilirubin have an increased exposure to unbound drug, but without a reduction in total systemic clearance of the drug, possibly because of enhanced renal clearance [<a href="#rid174">174,176,177</a>].</p><p>Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States Prescribing Information. Some clinicians recommend a 50 percent dose reduction for patients with a serum bilirubin 1.5 to 3 mg/dL or AST &gt;3 times ULN [<a href="#rid58">58,109</a>], and reduction or omission of the dose for higher bilirubin levels.</p><p>Low albumin levels (&lt;3.5 g/dL) are associated with an increase in the fraction of free drug, and this may lead to more pronounced hematologic toxicity [<a href="#rid178">178,179</a>]. A dose reduction by 33 or 50 percent has been recommended for patients with a reduced serum albumin [<a href="#rid109">109,178</a>].</p><p class="headingAnchor" id="H36"><span class="h3">Taxanes</span></p><p class="headingAnchor" id="H714826"><span class="h4">Paclitaxel and docetaxel</span><span class="headingEndMark"> — </span>In patients with normal baseline LFTs who are treated with either <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> or <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>, transient elevations of alkaline phosphatase, AST, and bilirubin have been reported in approximately 5 to 20 percent of cases [<a href="#rid180">180</a>]. Hepatic toxicity is not dose dependent, and prolonged exposure to taxanes is not associated with cumulative hepatic toxicity.</p><p>Both <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> undergo oxidation by the hepatic cytochrome P450 system and are excreted in the bile [<a href="#rid181">181,182</a>]. Clinically significant interactions have been reported with other drugs that are metabolized by cytochrome P450, including inhibitors and inducers of CYP3A4  (<a class="graphic graphic_table graphicRef76992" href="/d/graphic/76992.html" rel="external">table 4</a>) [<a href="#rid183">183</a>].</p><p>Patients with slightly elevated alkaline phosphatase or aminotransferases have decreased <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> clearance and are at increased risk for severe treatment-related toxicity [<a href="#rid184">184,185</a>]. The impact of hepatic dysfunction on paclitaxel clearance varies depending upon the duration of drug infusion and the extent of liver abnormalities [<a href="#rid186">186-188</a>].</p><p>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D9ffd3e34-537f-4f65-b00e-57c25bab3b01&amp;token=wkMsh%2FeM4ol6jrYVdHE5koUKY%2FSicSGtzKCipmt9Qsq%2FsenqdwJc95BhXvpSyL19jdHJesZsOO%2BmVTnv0derBeRWmmpww4nInIOFIYFud2EMe9if%2BL0NQF3DnxZIx13A&amp;TOPIC_ID=2837" target="_blank">United States Prescribing Information</a> recommends the following dose modifications for preexisting liver disease in patients receiving three-hour infusions [<a href="#rid189">189</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Total bilirubin ≤1.25 times ULN <strong>and</strong> AST &lt;10 times ULN – total dose 175 mg/m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>Total bilirubin 1.26 to 2 times ULN <strong>and</strong> aminotransferases &lt;10 times ULN – total dose 135 mg/m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>Total bilirubin 2.01 to 5 times ULN <strong>and</strong> aminotransferases &lt;10 times ULN – total dose 90 mg/m<sup>2</sup></p><p class="bulletIndent1"><span class="glyph">●</span>Total bilirubin &gt;5 times ULN <strong>or</strong> aminotransferases ≥10 times ULN – not recommended</p><p></p><p>None of the data used to derive these guidelines were from patients treated with <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> over one hour or with weekly therapy. It is unknown if these dose reduction schema are suitable for such patients, and further studies with a prospective design are needed.</p><p>For <a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">nabpaclitaxel</a> (Abraxane), the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D24d10449-2936-4cd3-b7db-a7683db721e4&amp;token=sgZE2%2FVb6zfL0sBmluSW5OtK4r%2FqC3V2VyItZyqPNkDuJ9YVpit%2FGPe9q1%2BYYPr%2BXqm7Wy7HBoVHPt2DBefqmSwj2OTbr1h6xcyV5NZWreGvNcziRWs5gidAonNSEEqL&amp;TOPIC_ID=2837" target="_blank">United States Prescribing Information</a> recommends reduced initial doses in patients with any malignancy who have severe hepatic impairment (AST &gt;10 times ULN <strong>or</strong> bilirubin &gt;5 times ULN); they also recommend not administering the drug to patients with pancreatic cancer who have moderate or severe hepatic impairment (ALT &lt;10 times ULN and total bilirubin &gt;1.5 times ULN, or ALT &gt;10 times ULN).</p><p>Decreased <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> clearance occurs in patients with elevated bilirubin and/or transaminase levels. In some studies, even a slight or moderate increase in pretreatment bilirubin level was associated with toxic deaths [<a href="#rid190">190-192</a>].</p><p>Guidelines for dose reduction in the setting of hepatic dysfunction are variable:</p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F022534s011lbl.pdf&amp;token=jVrbpECV7vVQf9GfOGOsg3ysAJf7nqfiIM8KYLBRtgGGRMjtLksuwziKFNYXMQnFtkbvXCuY%2FP7bDk8onnRxnjp5EqLN5RASfPlFgCAKgZQ%3D&amp;TOPIC_ID=2837" target="_blank">United States Prescribing Information</a> suggests that <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> not be given if the baseline serum bilirubin is above the ULN, or to patients with AST &gt;1.5 times ULN in conjunction with an alkaline phosphatase &gt;2.5 times ULN. Furthermore, because elevations in LFTs increase the risk of severe or life-threatening complications, LFTs should be obtained prior to each treatment cycle. </p><p></p><p class="bulletIndent1">In the specific setting of gastric cancer when <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> is administered in conjunction with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and FU, a 20 percent dose reduction is recommended in patients who develop aminotransferase elevation &gt;2.5 to ≤5 times ULN and alkaline phosphatase ≤2.5 times ULN, or aminotransferases &gt;1.5 to ≤5 times ULN and alkaline phosphatase &gt;2.5 to ≤5 times ULN [<a href="#rid193">193</a>]. For more severe hepatic dysfunction, drug discontinuation is recommended.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Based upon pharmacokinetic modeling, others have recommended a 20 to 40 percent dose reduction for patients with grade 2 or 3 elevations in aminotransferases (&gt;2.5 to 20 times ULN,  (<a class="graphic graphic_table graphicRef77533" href="/d/graphic/77533.html" rel="external">table 1</a>)) at baseline in conjunction with elevated levels of alkaline phosphatase [<a href="#rid194">194</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A dose modification scheme for weekly <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> administration based upon preexisting liver dysfunction has been proposed for Asian patients [<a href="#rid195">195</a>].</p><p></p><p>Whether <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> is contraindicated in patients with severe liver dysfunction on the basis of metastatic cancer involvement is unclear. Administration of reduced-dose docetaxel has been successful in at least one report of a patient with breast cancer metastasis-related severe liver dysfunction [<a href="#rid196">196</a>].</p><p class="headingAnchor" id="H714836"><span class="h4">Cabazitaxel</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="15577" href="/d/drug information/15577.html" rel="external">Cabazitaxel</a> is a semisynthetic taxane that is approved for treatment of advanced prostate cancer. There is no published experience with cabazitaxel in patients with impaired hepatic function. However, cabazitaxel is extensively metabolized by the liver, and hepatic impairment is likely to increase exposure to the drug. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Dde3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa&amp;token=Li%2Fbil6wzP5mK16t7HqJYtmJNWvHgMXMPK581qSrHZEb6tWlHL4hH%2F%2F4Y3VyGbhakMDNPm3H2xDRrI46YfZ3u8DtH16pch3zRkIbgYibQP7HhgFtJi%2Fj4oVBlC8FgI2y&amp;TOPIC_ID=2837" target="_blank">United States Prescribing Information</a> suggests that the drug not be administered to patients with bilirubin levels more than 3 times ULN and that the starting dose be reduced in those with mild or moderate hepatic impairment (any bilirubin level above the ULN or AST &gt;1.5 times ULN).</p><p class="headingAnchor" id="H37"><span class="h3">Ixabepilone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8909" href="/d/drug information/8909.html" rel="external">Ixabepilone</a> is a microtubule inhibitor in the epothilone class that has been approved for treatment of chemotherapy resistant patients with metastatic breast cancer. </p><p><a class="drug drug_general" data-topicid="8909" href="/d/drug information/8909.html" rel="external">Ixabepilone</a> is metabolized in the liver, and drug exposure is significantly increased in patients with hepatic disease [<a href="#rid197">197</a>]. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D241f0b1e-8b95-470d-876f-bf1804daaf18&amp;token=Jr8qSi%2F7FAA3hICspFoHbXHnwJvbhbwUGCSFLU2Qskq3HUo33nixqLTZZ%2FkfBe6JgjxPA3BB%2FltdAFr2%2B9C8rHNOvuFFxWpczwvjy3ZU6WUGWNWUrwcecAQdz9EGaKWZ&amp;TOPIC_ID=2837" target="_blank">United States Prescribing Information</a> for initial dose modification for ixabepilone monotherapy is indicated in the table  (<a class="graphic graphic_table graphicRef69104" href="/d/graphic/69104.html" rel="external">table 2</a>). Subsequent dosing should be based upon treatment tolerance. Ixabepilone monotherapy is not recommended for aminotransferases &gt;10 times ULN, or bilirubin &gt;3 times ULN. The combination of ixabepilone with <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> is contraindicated in patients with aminotransferase elevation ≥2.5 times ULN or serum bilirubin above the ULN.</p><p class="headingAnchor" id="H742022"><span class="h3">Eribulin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16096" href="/d/drug information/16096.html" rel="external">Eribulin</a> mesylate, a synthetic analogue of halichondrin B, a substance derived from a marine sponge, inhibits the polymerization of tubulin and microtubules. Eribulin exposure is increased in patients with mild and moderate hepatic impairment [<a href="#rid198">198</a>]. Dose modification is recommended in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D8fc8fe1d-59fe-4e43-a95c-e7aa13422cd6&amp;token=%2BZO3ccX9O4dQtKSwk6BXBqjZO%2BjVLMrnwJPmogNH08VaG2R68Vd1b1aNeX4q%2BfyTyHxTXAHJevR3kJudTxbsXST3l7yCmnzj4KtiEBeDpN2456v7vOmkIdcKyKCzi1Uf&amp;TOPIC_ID=2837" target="_blank">United States Prescribing Information</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>Child-Pugh A disease  (<a class="graphic graphic_table graphicRef78401" href="/d/graphic/78401.html" rel="external">table 5</a>) – decrease in initial dose to 1.1 mg/m<sup>2</sup> </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Child-Pugh B disease – decrease initial dose to 0.7 mg/m<sup>2</sup></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Child-Pugh C disease – do not administer</p><p></p><p class="headingAnchor" id="H38"><span class="h2">Miscellaneous agents</span></p><p class="headingAnchor" id="H39"><span class="h3">Bortezomib and other proteasome inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">Bortezomib</a> is predominantly metabolized by the liver, and exposure is increased in patients with moderate to severe liver impairment [<a href="#rid199">199</a>]. <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D042329d6-8077-4af2-816f-cd0a2bbcbbd3&amp;token=aeep5ZKdItxpk1uyTMtLee6tPQIZvAti%2Botc1HYxrMCx4LQZ6SteqXmS7kp04k8KmBbxvIphqPyHsC4ZGLGLkC%2FlqvaCpc%2Fz3u3HxOv7vIH46ojfS7V8Ug2jZNYgYo%2F0&amp;TOPIC_ID=2837" target="_blank">United States Prescribing Information</a> suggests a reduced starting dose (0.7 mg/m<sup>2</sup>) in the first cycle for patients with a serum bilirubin &gt;1.5 times ULN, with dose escalation or further dose reduction in subsequent cycles based upon patient tolerability. (See  <a class="medical medical_review" href="/d/html/131450.html" rel="external">"Multiple myeloma: Administration considerations for common therapies", section on 'Proteasome inhibitors'</a>.)</p><p>A reduced starting dose is also recommended for patients with moderate or severe hepatic impairment who are treated with the orally active proteasome inhibitor <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D038f2461-834b-4488-9ebd-863c83eef5a7&amp;token=W4Dtg0JrAC8zRdugP%2FQF0%2F4TqOhWiML4mfSwdKDgB6%2BuZ2rvl%2FhR%2B%2Bj5PJk3DAF9aW05cwViM93iDliIg01qEkTjakZMWmkhK6TH1X7TR%2Bw4fDu9xYw4Nhy55pRsmjYA&amp;TOPIC_ID=2837" target="_blank">ixazomib</a>. In addition, periodic monitoring of hepatic enzymes during therapy with both <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D038f2461-834b-4488-9ebd-863c83eef5a7&amp;token=W4Dtg0JrAC8zRdugP%2FQF0%2F4TqOhWiML4mfSwdKDgB6%2BuZ2rvl%2FhR%2B%2Bj5PJk3DAF9aW05cwViM93iDliIg01qEkTjakZMWmkhK6TH1X7TR%2Bw4fDu9xYw4Nhy55pRsmjYA&amp;TOPIC_ID=2837" target="_blank">ixazomib</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Dea66eb30-e665-4693-99a1-a9d3b4bbe2d6&amp;token=gH1mZVvRofJg1pa9gDqZTLEHynBlcoZ4%2FJV3Nj0p6xjLRuDK7LVHu%2BtXFG7pyGMe6HJMQUGNdOfZBkFMpSxKq6Sa9dR3IwcF%2FVJgR2W1tuJLceyPVOC01%2BxNkfNB1JKA&amp;TOPIC_ID=2837" target="_blank">carfilzomib</a> is recommended, given reports of drug-induced liver injury in &lt;1 percent of treated patients. </p><p class="headingAnchor" id="H40"><span class="h3">Irinotecan and liposomal irinotecan</span><span class="headingEndMark"> — </span>Combinations of <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> and FU are used in some patients with colorectal cancer prior to the resection of liver metastases. These regimens have been associated with both steatosis and hepatic vascular injury. (See  <a class="medical medical_review" href="/d/html/2483.html" rel="external">"Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Post-treatment assessment and duration of neoadjuvant therapy'</a>.)</p><p><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2015%2F207793lbl.pdf%3Fet_cid%3D36866849%26et_rid%3D907466112%26linkid%3Dhttp%253a%252f%252fwww.accessdata.fda.gov%252fdrugsatfda_docs%252flabel%252f2015%252f207793lbl.pdf&amp;token=idUVoJnkJSrhD%2FdIljT%2B4JPFsuG7DdH%2BmzQQGpQlrJCBEoyQi7TYr%2BFVvD1vh5szofdfu2UrWP6Q0RV%2FqDA70ptbLjkKXtuFcxsN6p96RKREJuUxb0PCGB6v9L3PHVhr73pIdkLWVkXpwTXGjmWZhsVztITXIhTPrnn%2F8PgA3LRPQtMfR6gIrW5Mg4VyQq94&amp;TOPIC_ID=2837" target="_blank">Nanoliposome-encapsulated irinotecan</a> is approved in combination with FU plus <a class="drug drug_general" data-topicid="9548" href="/d/drug information/9548.html" rel="external">leucovorin</a> for treatment of gemcitabine-refractory metastatic pancreatic cancer. Transaminase elevations are reported in approximately 57 percent of patients but are severe in only 6 percent. (See  <a class="medical medical_review" href="/d/html/2475.html" rel="external">"Initial systemic chemotherapy for metastatic exocrine pancreatic cancer"</a>.)</p><p><a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">Irinotecan</a> (whether liposome-encapsulated or not) is mainly eliminated by the liver and to a minor extent by the kidneys [<a href="#rid200">200,201</a>]. Two main metabolic pathways take place in the liver: conversion into inactive metabolites (via the CYP3A4 isoenzyme) and into the active metabolite SN-38 by carboxylesterase enzymes. Irinotecan clearance is diminished in patients with hepatic dysfunction, and exposure to the active metabolite SN-38 is increased relative to that in patients with normal hepatic function.</p><p>The tolerability of <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> in patients with hepatic dysfunction (serum bilirubin &gt;2 mg/dL) has not been established. Specific dosing guidelines for patients with hepatic insufficiency are not available in the United States Prescribing Information for either unencapsulated irinotecan or <a class="drug drug_general" data-topicid="104962" href="/d/drug information/104962.html" rel="external">liposomal irinotecan</a>. </p><p>However, some clinicians recommend a reduction of the starting dose of unencapsulated <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a> (eg, from 350 mg/m<sup>2</sup> to 200 mg/m<sup>2</sup> every three weeks) in patients with a pretreatment serum bilirubin level 1.5 to 3 times ULN to minimize the likelihood of diarrhea and neutropenia [<a href="#rid109">109,201,202</a>]. Dose reduction may also be needed for patients with a serum bilirubin 1 to 1.5 mg/dL, particularly with weekly administration schedules [<a href="#rid203">203,204</a>]. The United States Prescribing Information for <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2015%2F207793lbl.pdf%3Fet_cid%3D36866849%26et_rid%3D907466112%26linkid%3Dhttp%253a%252f%252fwww.accessdata.fda.gov%252fdrugsatfda_docs%252flabel%252f2015%252f207793lbl.pdf&amp;token=idUVoJnkJSrhD%2FdIljT%2B4JPFsuG7DdH%2BmzQQGpQlrJCBEoyQi7TYr%2BFVvD1vh5szofdfu2UrWP6Q0RV%2FqDA70ptbLjkKXtuFcxsN6p96RKREJuUxb0PCGB6v9L3PHVhr73pIdkLWVkXpwTXGjmWZhsVztITXIhTPrnn%2F8PgA3LRPQtMfR6gIrW5Mg4VyQq94&amp;TOPIC_ID=2837" target="_blank">liposomal irinotecan</a> states only that "there is no recommended dose of the drug for patients with serum bilirubin above the upper limit of normal."</p><p>Patients with elevated aminotransferases do not appear to be more sensitive to <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>, and dose reduction is probably not needed [<a href="#rid202">202</a>]. However, the available data are insufficient to make a specific recommendation.</p><p class="headingAnchor" id="H41"><span class="h3">Platinum derivatives</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">Cisplatin</a> is a rare cause of steatosis and cholestasis at standard doses [<a href="#rid205">205</a>]. Minor transient elevations in transaminases can occur during treatment [<a href="#rid206">206</a>] and are more frequent at higher doses [<a href="#rid207">207</a>]. Mild reversible increases in alkaline phosphatase and serum aminotransferases have also been reported with <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> and <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>. There is at least one report of carboplatin-induced liver failure [<a href="#rid208">208</a>] and one autopsy-documented case of hepatic SOS in a patient who received high-dose carboplatin and <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> in addition to multiple other medications [<a href="#rid209">209</a>]. (See <a class="local">'Hepatic vascular injury'</a> above.)</p><p>Combinations of <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> and FU are used in some patients with colorectal cancer prior to the resection of liver metastases. These neoadjuvant regimens have been associated with hepatic vascular injury, and nodular regenerative hyperplasia (now termed idiopathic noncirrhotic portal hypertension [including nodular regenerative hyperplasia]). (See <a class="local">'Hepatic vascular injury'</a> above and  <a class="medical medical_review" href="/d/html/3580.html" rel="external">"Noncirrhotic portal hypertension", section on 'Idiopathic noncirrhotic portal hypertension/Porto-sinusoidal vascular disease'</a> and  <a class="medical medical_review" href="/d/html/2483.html" rel="external">"Potentially resectable colorectal cancer liver metastases: Integration of surgery and chemotherapy", section on 'Post-treatment assessment and duration of neoadjuvant therapy'</a>.)</p><p>All three drugs are predominantly renally excreted. No published studies are available to guide dosing in patients with liver dysfunction. Results from single case reports, clinical trials conducted in patients with metastatic colorectal cancer, and from a dose-escalating and pharmacologic study in patients with various tumor types indicate that <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> can be administered without dose modification, even in patients with severe liver dysfunction [<a href="#rid210">210-212</a>]. </p><p class="headingAnchor" id="H42"><span class="h3">Asparaginase</span><span class="headingEndMark"> — </span>Hepatotoxicity is frequent with Escherichia coli-derived L-asparaginase (L-asp). Hepatotoxicity is characterized by moderate reversible elevation of aminotransferases, bilirubin, and/or alkaline phosphatase. Hyperammonemia may develop as asparagine is broken down.</p><p>The mechanism is uncertain, but probably involves impaired protein synthesis from asparagine depletion. Liver steatosis, likely due to decreased lipoprotein synthesis, is found at autopsy in 42 to 87 percent of treated patients [<a href="#rid213">213,214</a>]. Some series describe a lower likelihood of abnormalities of LFTs following administration of pegylated-L-asp (<a class="drug drug_general" data-topicid="9745" href="/d/drug information/9745.html" rel="external">Pegaspargase</a>) [<a href="#rid215">215</a>], but others describe a high frequency of grade 3 or 4 transaminitis (63 percent) and hyperbilirubinemia (31 percent) [<a href="#rid216">216</a>]. Recovery may be prolonged.</p><p>Systemic clearance of L-asp is not dependent on renal or liver function. As a result, dose modifications are not usually required.</p><p class="headingAnchor" id="H43"><span class="h3">Procarbazine</span><span class="headingEndMark"> — </span>Hepatotoxicity appears to be uncommon with <a class="drug drug_general" data-topicid="9815" href="/d/drug information/9815.html" rel="external">procarbazine</a> [<a href="#rid217">217</a>]. The drug has been implicated as a cause of granulomatous hepatitis [<a href="#rid218">218</a>].</p><p>Following oral administration, most <a class="drug drug_general" data-topicid="9815" href="/d/drug information/9815.html" rel="external">procarbazine</a> is rapidly converted to azo-procarbazine by erythrocyte and hepatic microsomal enzymes. Further metabolism has not been clearly defined. Although dose modification in patients with hepatic dysfunction is probably advisable, no formal guidelines have been published.</p><p class="headingAnchor" id="H1507796661"><span class="h3">Lenalidomide and pomalidomide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">Lenalidomide</a> and <a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">pomalidomide</a> are <a class="drug drug_general" data-topicid="10095" href="/d/drug information/10095.html" rel="external">thalidomide</a> analogs that are approved for treatment of multiple myeloma; pomalidomide is also approved for Kaposi sarcoma. (See  <a class="medical medical_review" href="/d/html/8034.html" rel="external">"AIDS-related Kaposi sarcoma: Staging and treatment", section on 'Subsequent therapy'</a> and  <a class="medical medical_review" href="/d/html/121127.html" rel="external">"Multiple myeloma: Treatment of first or second relapse", section on 'Bortezomib, pomalidomide, dexamethasone (VPd)'</a>.)</p><p>Potentially fatal hepatotoxicity is reported with both drugs, and LFTs should be monitored periodically during therapy. </p><p>Because <a class="drug drug_general" data-topicid="88099" href="/d/drug information/88099.html" rel="external">pomalidomide</a> is metabolized primarily by the liver, dose adjustment is recommended in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F204026s023lbl.pdf&amp;token=nvNFd4poKrogbgeqJIGVE%2BFc0ei4KNLuXaZ8DOx%2FrmQfmcBUP3pyTVk4S5c52UxFoJBUkBqAzNr9al8%2B%2Bmovdluv6OxR7W0BNsXQjaiQVgE%3D&amp;TOPIC_ID=2837" target="_blank">United States Prescribing Information</a> for mild, moderate, or severe preexisting hepatic impairment. On the other hand, the elimination of <a class="drug drug_general" data-topicid="9822" href="/d/drug information/9822.html" rel="external">lenalidomide</a> is predominantly by the renal route, and the United States Prescribing Information does not specify the need for dose reduction in those with hepatic insufficiency. </p><p class="headingAnchor" id="H44"><span class="h3">Hydroxyurea</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">Hydroxyurea</a> has been rarely reported to produce liver toxicity [<a href="#rid219">219-221</a>]. One case report describes hydroxyurea-induced hypersensitivity hepatitis with recurrence upon rechallenge [<a href="#rid220">220</a>].</p><p><a class="drug drug_general" data-topicid="8543" href="/d/drug information/8543.html" rel="external">Hydroxyurea</a> is well absorbed from the gastrointestinal tract, and 50 percent of the drug is excreted unchanged in the urine. There are no published guidelines for dose reduction in patients with liver dysfunction.</p><p class="headingAnchor" id="H627314962"><span class="h3">Arsenic trioxide</span><span class="headingEndMark"> — </span>On the basis of limited data from patients receiving <a class="drug drug_general" data-topicid="8977" href="/d/drug information/8977.html" rel="external">arsenic trioxide</a> for hepatocellular cancer, there appears to be no clear trend toward an increase in systemic exposure to the pharmacologically active metabolites of arsenic trioxide with decreasing levels of hepatic function [<a href="#rid222">222</a>]. Nevertheless, given the limited amount of available data, caution is advised in the use of the drug in patients with hepatic impairment, and patients with severe hepatic impairment (eg, Child-Pugh C cirrhosis  (<a class="graphic graphic_table graphicRef78401" href="/d/graphic/78401.html" rel="external">table 5</a>)) should be closely monitored for toxicity.</p><p class="headingAnchor" id="H459304121"><span class="h3">Vorinostat and belinostat</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9491" href="/d/drug information/9491.html" rel="external">Vorinostat</a> is an inhibitor of histone deacetylase enzymes; it is used only for treatment of cutaneous T-cell lymphoma. (See  <a class="medical medical_review" href="/d/html/4759.html" rel="external">"Treatment of advanced stage (IIB to IV) mycosis fungoides", section on 'Vorinostat'</a>.)</p><p>Patients with varying degrees of hepatic dysfunction require dose reduction even though <a class="drug drug_general" data-topicid="9491" href="/d/drug information/9491.html" rel="external">vorinostat</a> pharmacokinetics are unaltered [<a href="#rid223">223</a>]. <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Dcd86ee78-2781-468b-930c-3c4677bcc092&amp;token=1XcHWQWPFJjJmUUfw50FskPhiXJpaDjXqxtQPMw2jFb%2FqT2ByTCW5MsAqb4itb0Ae7q1o9Q9yV19YbkrSr9hMjXhYlXtUSArhsPqFnLi3dwB9rd8%2Fr%2FkwFedo38Xral0&amp;TOPIC_ID=2837" target="_blank">United States Prescribing Information</a> for vorinostat recommends reduced doses for patients with mild to moderate hepatic impairment (total bilirubin &gt;1 to 3 times ULN) and that the drug be avoided in those with severe impairment (total bilirubin &gt;3 times ULN). Canadian guidelines recommend avoidance of the drug for all patients with total bilirubin ≥1.5 times ULN.</p><p><a class="drug drug_general" data-topicid="96188" href="/d/drug information/96188.html" rel="external">Belinostat</a> is another histone deacetylase inhibitor that is approved for treatment of peripheral T-cell lymphoma. Belinostat can cause potentially fatal hepatotoxicity (there was one fatality from hepatic failure in 129 treated patients [<a href="#rid224">224</a>]). LFTs should be checked before treatment and before the start of each cycle; dose reduction is recommended for any grade 3 or worse toxicity  (<a class="graphic graphic_table graphicRef77533" href="/d/graphic/77533.html" rel="external">table 1</a>).</p><p><a class="drug drug_general" data-topicid="96188" href="/d/drug information/96188.html" rel="external">Belinostat</a> is metabolized in the liver, and hepatic impairment is likely to increase drug exposure. Patients with moderate to severe hepatic impairment were excluded from clinical trials, and there are insufficient data to recommend a belinostat dose in these patients.</p><p class="headingAnchor" id="H605323938"><span class="h3">Trabectedin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9513" href="/d/drug information/9513.html" rel="external">Trabectedin</a> (ecteinascidin, ET-743), which is now synthesized, was originally isolated from the Caribbean sea sponge <em>Ecteinascidia turbinata</em>; it kills cells by poisoning the DNA nucleotide excision repair machinery and is an active agent for advanced STS. (See  <a class="medical medical_review" href="/d/html/139327.html" rel="external">"Second and later lines of therapy for metastatic soft tissue sarcoma", section on 'Trabectedin (LMS)'</a>.)</p><p>Severe hepatotoxicity, including hepatic failure, can occur in patients treated with <a class="drug drug_general" data-topicid="9513" href="/d/drug information/9513.html" rel="external">trabectedin</a>. In one trial, over 35 percent of patients had a grade 3 or 4 elevation in transaminases during therapy [<a href="#rid225">225</a>], despite pretreatment with high-dose <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a>. Dexamethasone is recommended prior to each dose of the drug and has been shown to mitigate severe hepatotoxicity with this agent [<a href="#rid226">226</a>]. </p><p>LFTs should be assessed prior to each dose of <a class="drug drug_general" data-topicid="9513" href="/d/drug information/9513.html" rel="external">trabectedin</a>. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D472bd78e-be17-4b9d-90f4-9482c3aec9ff&amp;token=FGDCJ3EnrI50N5eop5oYgYpIAg8Zwvc5FlbuuYfPHo9jz9wr5m4SuEmq4PbX16y0CuMW%2FlBnJ%2Be2kRDbuQzN%2B2CGVAeqf7rUgp1oN46KZkOXPQnyAoZ7AQhamQIW4Lbi&amp;TOPIC_ID=2837" target="_blank">United States Prescribing Information</a> includes recommended dose modifications for hepatotoxicity during therapy.</p><p class="headingAnchor" id="H1871946787"><span class="h1">COMBINATION CHEMOTHERAPY REGIMENS</span><span class="headingEndMark"> — </span>The majority of tumors are treated with combination rather than single-agent therapy; typically, the individual agents have different mechanisms of action and toxicity profiles. The potential for greater tumor cell kill is sometimes accompanied by greater toxicity, including hepatotoxicity.</p><p>For patients who develop hepatotoxicity while receiving a regimen with multiple drugs, it may not be immediately apparent which agent is responsible, and it is prudent to withhold all drugs until hepatotoxicity is reversed. If needed, dose adjustment for the next course should be undertaken for all drugs that might have been responsible for the hepatotoxicity, not just the most likely culprit. </p><p class="headingAnchor" id="H849606194"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/17191.html" rel="external">"Patient education: Drug-induced hepatitis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H601311239"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Chemotherapy agents, either alone or in combination with other drugs and radiation, may cause indirect or direct hepatotoxicity. Furthermore, abnormal liver function may alter drug metabolism and increase the risk of extrahepatic toxicity. (See <a class="local">'Mechanisms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Guidelines on dose modification for patients with preexisting hepatic disease are largely empiric. For some agents, including <a class="drug drug_general" data-topicid="9323" href="/d/drug information/9323.html" rel="external">bendamustine</a>, <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a> and <a class="drug drug_general" data-topicid="9530" href="/d/drug information/9530.html" rel="external">pralatrexate</a>, the vinca alkaloids, taxanes, <a class="drug drug_general" data-topicid="9815" href="/d/drug information/9815.html" rel="external">procarbazine</a>, <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="105607" href="/d/drug information/105607.html" rel="external">ixazomib</a>, <a class="drug drug_general" data-topicid="86042" href="/d/drug information/86042.html" rel="external">carfilzomib</a>, anthracyclines, <a class="drug drug_general" data-topicid="9491" href="/d/drug information/9491.html" rel="external">vorinostat</a>, <a class="drug drug_general" data-topicid="8909" href="/d/drug information/8909.html" rel="external">ixabepilone</a>, and <a class="drug drug_general" data-topicid="9513" href="/d/drug information/9513.html" rel="external">trabectedin</a>, there is agreement on the need for dose adjustment (or avoidance altogether) in patients with preexisting liver dysfunction in order to avoid excessive systemic toxicity  (<a class="graphic graphic_table graphicRef69104" href="/d/graphic/69104.html" rel="external">table 2</a>). (See <a class="local">'Dose reduction for patients with baseline hepatic impairment'</a> above.)</p><p></p><p class="bulletIndent1">There is less agreement on the need for dose reduction for other agents whose clearance is dependent upon liver metabolism, such as <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="8552" href="/d/drug information/8552.html" rel="external">ifosfamide</a>, <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>, <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, <a class="drug drug_general" data-topicid="9318" href="/d/drug information/9318.html" rel="external">dactinomycin</a>, <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a>, <a class="drug drug_general" data-topicid="8573" href="/d/drug information/8573.html" rel="external">irinotecan</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9815" href="/d/drug information/9815.html" rel="external">procarbazine</a>, and <a class="drug drug_general" data-topicid="9612" href="/d/drug information/9612.html" rel="external">6-mercaptopurine</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infection with hepatitis B (HBV) or hepatitis C (HCV) is a common disorder that can be exacerbated with cytotoxic chemotherapy. We agree with an updated year 2020 provisional clinical opinion from the American Society of Clinical Oncology, which endorses universal HBV screening for all patients beginning systemic anticancer therapy (cytotoxic chemotherapy, immunotherapy, molecularly targeted therapy) using three tests: hepatitis B surface antigen (HbSAg), hepatitis B core antibody (anti-HBc) total immunoglobulin (Ig) or IgG, and antibody to hepatitis B surface antigen (anti-HBs). The finding of chronic or past HBV infection requires HBV reactivation risk assessment to determine the need for antiviral prophylaxis. The recommended approach to HBV screening, monitoring, and antiviral prophylaxis is outlined in the algorithm  (<a class="graphic graphic_algorithm graphicRef129226" href="/d/graphic/129226.html" rel="external">algorithm 1</a>). (See <a class="local">'HBV screening and management'</a> above.)</p><p></p><p class="bulletIndent1">Clinicians should also consider testing for chronic hepatitis C virus infection prior to initiating potentially immunosuppressive chemotherapy, although the data are less compelling than for HBV testing. Patients with chronic HCV infection who are receiving chemotherapy should undergo serial monitoring of LFTs, and if there is no dramatic change, continued chemotherapy treatment without dose modification is appropriate. (See <a class="local">'Hepatitis C'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995; 333:1118.</a></li><li><a class="nounderline abstract_t">Fischer MA, Winkelmayer WC, Rubin RH, Avorn J. The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Clin Infect Dis 2005; 41:301.</a></li><li><a class="nounderline abstract_t">Chamilos G, Luna M, Lewis RE, et al. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study. Clin Ther 2007; 29:1980.</a></li><li><a class="nounderline abstract_t">Umrethia M, Ghosh PK, Majithya R, Murthy RS. 6-mercaptopurine (6-MP) entrapped stealth liposomes for improvement of leukemic treatment without hepatotoxicity and nephrotoxicity. Cancer Invest 2007; 25:117.</a></li><li><a class="nounderline abstract_t">Erichsen C, Jönsson PE. Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma. J Surg Oncol 1984; 27:268.</a></li><li><a class="nounderline abstract_t">Greenstone MA, Dowd PM, Mikhailidis DP, Scheuer PJ. Hepatic vascular lesions associated with dacarbazine treatment. Br Med J (Clin Res Ed) 1981; 282:1744.</a></li><li><a class="nounderline abstract_t">Asbury RF, Rosenthal SN, Descalzi ME, et al. Hepatic veno-occlusive disease due to DTIC. Cancer 1980; 45:2670.</a></li><li><a class="nounderline abstract_t">Ceci G, Bella M, Melissari M, et al. Fatal hepatic vascular toxicity of DTIC. Is it really a rare event? Cancer 1988; 61:1988.</a></li><li><a class="nounderline abstract_t">Sutherland CM, Krementz ET. Hepatic toxicity of DTIC. Cancer Treat Rep 1981; 65:321.</a></li><li><a class="nounderline abstract_t">Féaux de Lacroix W, Runne U, Hauk H, et al. Acute liver dystrophy with thrombosis of hepatic veins: a fatal complication of dacarbazine treatment. Cancer Treat Rep 1983; 67:779.</a></li><li><a class="nounderline abstract_t">Raine J, Bowman A, Wallendszus K, Pritchard J. Hepatopathy-thrombocytopenia syndrome--a complication of dactinomycin therapy for Wilms' tumor: a report from the United Kingdom Childrens Cancer Study Group. J Clin Oncol 1991; 9:268.</a></li><li><a class="nounderline abstract_t">Joensuu H, Söderström KO, Nikkanen V. Fatal necrosis of the liver during ABVD chemotherapy for Hodgkin's disease. A case report. Cancer 1986; 58:1437.</a></li><li><a class="nounderline abstract_t">Houghton AN, Shafi N, Rickles FR. Acute hepatic vein thrombosis occurring during therapy for Hodgkin's disease: a case report. Cancer 1979; 44:2324.</a></li><li><a class="nounderline abstract_t">Gill RA, Onstad GR, Cardamone JM, et al. Hepatic veno-occlusive disease caused by 6-thioguanine. Ann Intern Med 1982; 96:58.</a></li><li><a class="nounderline abstract_t">Stoneham S, Lennard L, Coen P, et al. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia. Br J Haematol 2003; 123:100.</a></li><li><a class="nounderline abstract_t">Read AE, Wiesner RH, LaBrecque DR, et al. Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy. Ann Intern Med 1986; 104:651.</a></li><li><a class="nounderline abstract_t">Sterneck M, Wiesner R, Ascher N, et al. Azathioprine hepatotoxicity after liver transplantation. Hepatology 1991; 14:806.</a></li><li><a class="nounderline abstract_t">Overman MJ, Maru DM, Charnsangavej C, et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 2010; 28:2549.</a></li><li><a class="nounderline abstract_t">Mehta NN, Ravikumar R, Coldham CA, et al. Effect of preoperative chemotherapy on liver resection for colorectal liver metastases. Eur J Surg Oncol 2008; 34:782.</a></li><li><a class="nounderline abstract_t">Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008; 247:118.</a></li><li><a class="nounderline abstract_t">Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24:2065.</a></li><li><a class="nounderline abstract_t">Slade JH, Alattar ML, Fogelman DR, et al. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer 2009; 8:225.</a></li><li><a class="nounderline abstract_t">Khozouz RF, Huq SZ, Perry MC. Radiation-induced liver disease. J Clin Oncol 2008; 26:4844.</a></li><li><a class="nounderline abstract_t">Hansen MM, Ranek L, Walbom S, Nissen NI. Fatal hepatitis following irradiation and vincristine. Acta Med Scand 1982; 212:171.</a></li><li><a class="nounderline abstract_t">Kun LE, Camitta BM. Hepatopathy following irradiation and adriamycin. Cancer 1978; 42:81.</a></li><li><a class="nounderline abstract_t">Ishak KG, Zimmerman HJ. Morphologic spectrum of drug-induced hepatic disease. Gastroenterol Clin North Am 1995; 24:759.</a></li><li><a class="nounderline abstract_t">Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11:272.</a></li><li><a class="nounderline abstract_t">Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26:664.</a></li><li><a class="nounderline abstract_t">Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000; 342:1266.</a></li><li><a class="nounderline abstract_t">Ramsey SD, Unger JM, Baker LH, et al. Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices. JAMA Oncol 2019; 5:497.</a></li><li><a class="nounderline abstract_t">Yeo W, Mo FK, Chan SL, et al. Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology 2007; 45:1382.</a></li><li><a class="nounderline abstract_t">Paul S, Saxena A, Terrin N, et al. Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis. Ann Intern Med 2016; 164:30.</a></li><li><a class="nounderline abstract_t">Voican CS, Mir O, Loulergue P, et al. Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Ann Oncol 2016; 27:2172.</a></li><li><a class="nounderline abstract_t">Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020; 38:3698.</a></li><li><a class="nounderline abstract_t">Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148:215.</a></li><li><a class="nounderline abstract_t">Hwang JP, Somerfield MR, Alston-Johnson DE, et al. Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. J Clin Oncol 2015; 33:2212.</a></li><li><a class="nounderline abstract_t">Di Bisceglie AM, Lok AS, Martin P, et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology 2015; 61:703.</a></li><li><a class="nounderline abstract_t">Hwang JP, Lok AS, Fisch MJ, et al. Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. J Clin Oncol 2018; 36:959.</a></li><li><a class="nounderline abstract_t">Brasseur M, Heurgué-Berlot A, Barbe C, et al. Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors. BMC Cancer 2015; 15:999.</a></li><li><a class="nounderline abstract_t">Hwang JP, Artz AS, Shah P, et al. Practical Implementation of Universal Hepatitis B Virus Screening for Patients With Cancer. JCO Oncol Pract 2022; 18:636.</a></li><li><a class="nounderline abstract_t">Vento S, Cainelli F, Mirandola F, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996; 347:92.</a></li><li><a class="nounderline abstract_t">de Pree C, Giostra E, Galetto A, et al. Hepatitis C virus acute exacerbation during chemotherapy and radiotherapy for oesophageal carcinoma. Ann Oncol 1994; 5:861.</a></li><li><a class="nounderline abstract_t">Melisko ME, Fox R, Venook A. Reactivation of hepatitis C virus after chemotherapy for colon cancer. Clin Oncol (R Coll Radiol) 2004; 16:204.</a></li><li><a class="nounderline abstract_t">Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 2012; 9:156.</a></li><li><a class="nounderline abstract_t">Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999; 46:2925.</a></li><li><a class="nounderline abstract_t">Kawatani T, Suou T, Tajima F, et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 2001; 67:45.</a></li><li><a class="nounderline abstract_t">Faggioli P, De Paschale M, Tocci A, et al. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma. Haematologica 1997; 82:38.</a></li><li><a class="nounderline abstract_t">Zuckerman E, Zuckerman T, Douer D, et al. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 1998; 83:1224.</a></li><li><a class="nounderline abstract_t">Khan S, Ramwani JJ, O'Brien PJ. Hepatocyte toxicity of mechlorethamine and other alkylating anticancer drugs. Role of lipid peroxidation. Biochem Pharmacol 1992; 43:1963.</a></li><li><a class="nounderline abstract_t">Aubrey DA. Massive hepatic necrosis after cyclophosphamide. Br Med J 1970; 3:588.</a></li><li><a class="nounderline abstract_t">Walters D, Robinson RG, Dick-Smith JB, et al. Poor response in two cases of juvenile rheumatoid arthritis to treatment with cyclophosphamide. Med J Aust 1972; 2:1070.</a></li><li><a class="nounderline abstract_t">Bacon AM, Rosenberg SA. Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus. Ann Intern Med 1982; 97:62.</a></li><li><a class="nounderline abstract_t">Goldberg JW, Lidsky MD. Cyclophosphamide-associated hepatotoxicity. South Med J 1985; 78:222.</a></li><li><a class="nounderline abstract_t">Snyder LS, Heigh RI, Anderson ML. Cyclophosphamide-induced hepatotoxicity in a patient with Wegener's granulomatosis. Mayo Clin Proc 1993; 68:1203.</a></li><li><a class="nounderline abstract_t">Shaunak S, Munro JM, Weinbren K, et al. Cyclophosphamide-induced liver necrosis: a possible interaction with azathioprine. Q J Med 1988; 67:309.</a></li><li><a class="nounderline abstract_t">Juma FD. Effect of liver failure on the pharmacokinetics of cyclophosphamide. Eur J Clin Pharmacol 1984; 26:591.</a></li><li><a class="nounderline abstract_t">Matthias M, Saul G. [Clinical aspects of the excretion of alkylating cyclophosphamide metabolites in the urine of tumor bearing patients]. Onkologie 1978; 1:41.</a></li><li><a class="nounderline abstract_t">Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. Semin Oncol 2006; 33:50.</a></li><li><a class="nounderline abstract_t">Paschke R, Worst P, Brust J, Queisser W. [Hepatotoxicity with etoposide-ifosfamide combination therapy]. Onkologie 1988; 11:273.</a></li><li class="breakAll">IFEX (sterile ifosfamide) package insert, Bristol-Myers Squibb.</li><li><a class="nounderline abstract_t">Falkson G, Hunt M, Borden EC, et al. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest New Drugs 1992; 10:337.</a></li><li class="breakAll">ZEPZELCA (lurbinectedin) for injection, for intravenous use. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf (Accessed on June 24, 2020).</li><li><a class="nounderline abstract_t">Jen JF, Cutler DL, Pai SM, et al. Population pharmacokinetics of temozolomide in cancer patients. Pharm Res 2000; 17:1284.</a></li><li><a class="nounderline abstract_t">Dixit S, Baker L, Walmsley V, Hingorani M. Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review. Anticancer Drugs 2012; 23:1099.</a></li><li><a class="nounderline abstract_t">Goldbecker A, Tryc AB, Raab P, et al. Hepatic encephalopathy after treatment with temozolomide. J Neurooncol 2011; 103:163.</a></li><li><a class="nounderline abstract_t">Dixit S, Hingorani M, Afzal P, Campbell AP. Temozolomide induced liver injury. Acta Neurol Belg 2011; 111:249.</a></li><li><a class="nounderline abstract_t">Sarganas G, Orzechowski HD, Klimpel A, et al. Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system. Neuro Oncol 2012; 14:541.</a></li><li><a class="nounderline abstract_t">Lazarus HM, Herzig RH, Graham-Pole J, et al. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J Clin Oncol 1983; 1:359.</a></li><li><a class="nounderline abstract_t">Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97:631.</a></li><li><a class="nounderline abstract_t">AMROMIN GD, DELIMAN RM, SHANBROM E. Liver damage after chemotherapy for leukemia and lymphoma. Gastroenterology 1962; 42:401.</a></li><li><a class="nounderline abstract_t">KOLER RD, FORSGREN AL. Hepatotoxicity due to chlorambucil; report of a case. J Am Med Assoc 1958; 167:316.</a></li><li><a class="nounderline abstract_t">Morris LE, Guthrie TH Jr. Busulfan-induced hepatitis. Am J Gastroenterol 1988; 83:682.</a></li><li><a class="nounderline abstract_t">Underwood JC, Shahani RT, Blackburn EK. Jaundice after treatment of leukemia with busulphan. Br Med J 1971; 1:556.</a></li><li><a class="nounderline abstract_t">Meredith MJ, Reed DJ. Depletion in vitro of mitochondrial glutathione in rat hepatocytes and enhancement of lipid peroxidation by adriamycin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem Pharmacol 1983; 32:1383.</a></li><li><a class="nounderline abstract_t">De Vita VT, Carbone PP, Owens AH Jr, et al. Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962. Cancer Res 1965; 25:1876.</a></li><li><a class="nounderline abstract_t">Phillips GL, Fay JW, Herzig GP, et al. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study. Cancer 1983; 52:1792.</a></li><li><a class="nounderline abstract_t">Hoogstraten B, Gottlieb JA, Caoili E, et al. CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, NSC-79037) in the treatment of cancer. Phase II study. Cancer 1973; 32:38.</a></li><li><a class="nounderline abstract_t">Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973; 79:108.</a></li><li><a class="nounderline abstract_t">Schein PS, O'Connell MJ, Blom J, et al. Clinical antitumor activity and toxicity of streptozotocin (NSC-85998). Cancer 1974; 34:993.</a></li><li><a class="nounderline abstract_t">Ellison RR, Holland JF, Weil M, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968; 32:507.</a></li><li><a class="nounderline abstract_t">Pizzuto J, Avilés A, Ramos E, et al. Cytosine arabinoside induced liver damage: histopathologic demonstration. Med Pediatr Oncol 1983; 11:287.</a></li><li><a class="nounderline abstract_t">George CB, Mansour RP, Redmond J 3rd, Gandara DR. Hepatic dysfunction and jaundice following high-dose cytosine arabinoside. Cancer 1984; 54:2360.</a></li><li><a class="nounderline abstract_t">Donehower RC, Karp JE, Burke PJ. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat Rep 1986; 70:1059.</a></li><li><a class="nounderline abstract_t">Kremer WB. Drugs five years later: cytarabine. Ann Intern Med 1975; 82:684.</a></li><li><a class="nounderline abstract_t">Kantarjian HM, Estey EH, Plunkett W, et al. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 1986; 81:387.</a></li><li><a class="nounderline abstract_t">Koren G, Beatty K, Seto A, et al. The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother 1992; 26:363.</a></li><li><a class="nounderline abstract_t">Bateman JR, Pugh RP, Cassidy FR, et al. 5-fluorouracil given once weekly: comparison of intravenous and oral administration. Cancer 1971; 28:907.</a></li><li><a class="nounderline abstract_t">Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001; 19:4097.</a></li><li><a class="nounderline abstract_t">Nikolic-Tomasevic Z, Jelic S, Cassidy J, et al. Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis. Cancer Chemother Pharmacol 2005; 56:594.</a></li><li><a class="nounderline abstract_t">Scheithauer W, McKendrick J, Begbie S, et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003; 14:1735.</a></li><li><a class="nounderline abstract_t">Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 1999; 5:1696.</a></li><li><a class="nounderline abstract_t">Hohn D, Melnick J, Stagg R, et al. Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine. J Clin Oncol 1985; 3:98.</a></li><li><a class="nounderline abstract_t">Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989; 7:1646.</a></li><li><a class="nounderline abstract_t">Martin JK Jr, O'Connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 1990; 125:1022.</a></li><li><a class="nounderline abstract_t">Doria MI Jr, Shepard KV, Levin B, Riddell RH. Liver pathology following hepatic arterial infusion chemotherapy. Hepatic toxicity with FUDR. Cancer 1986; 58:855.</a></li><li><a class="nounderline abstract_t">Kemeny N, Daly J, Reichman B, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 1987; 107:459.</a></li><li><a class="nounderline abstract_t">Chang AE, Schneider PD, Sugarbaker PH, et al. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987; 206:685.</a></li><li><a class="nounderline abstract_t">Ito K, Ito H, Kemeny NE, et al. Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. Ann Surg Oncol 2012; 19:1609.</a></li><li><a class="nounderline abstract_t">Kemeny MM, Battifora H, Blayney DW, et al. Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. Ann Surg 1985; 202:176.</a></li><li><a class="nounderline abstract_t">Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24:1395.</a></li><li><a class="nounderline abstract_t">Pettavel J, Gardiol D, Bergier N, Schnyder P. Fatal liver cirrhosis associated with long-term arterial infusion of floxuridine. Lancet 1986; 2:1162.</a></li><li><a class="nounderline abstract_t">Shepard KV, Levin B, Karl RC, et al. Therapy for metastatic colorectal cancer with hepatic artery infusion chemotherapy using a subcutaneous implanted pump. J Clin Oncol 1985; 3:161.</a></li><li><a class="nounderline abstract_t">Kemeny NE, Ron IG. Hepatic arterial chemotherapy in metastatic colorectal patients. Semin Oncol 1999; 26:524.</a></li><li><a class="nounderline abstract_t">Aapro MS, Martin C, Hatty S. Gemcitabine--a safety review. Anticancer Drugs 1998; 9:191.</a></li><li><a class="nounderline abstract_t">Robinson K, Lambiase L, Li J, et al. Fatal cholestatic liver failure associated with gemcitabine therapy. Dig Dis Sci 2003; 48:1804.</a></li><li><a class="nounderline abstract_t">Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000; 18:2780.</a></li><li><a class="nounderline abstract_t">Teusink AC, Hall PD. Toxicities of gemcitabine in patients with severe hepatic dysfunction. Ann Pharmacother 2010; 44:750.</a></li><li><a class="nounderline abstract_t">Pelzer U, Wislocka L, Jühling A, et al. Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospective analysis. Eur J Cancer 2018; 100:85.</a></li><li><a class="nounderline abstract_t">Superfin D, Iannucci AA, Davies AM. Commentary: Oncologic drugs in patients with organ dysfunction: a summary. Oncologist 2007; 12:1070.</a></li><li><a class="nounderline abstract_t">EINHORN M, DAVIDSOHN I. HEPATOTOXICITY OF MERCAPTOPURINE. JAMA 1964; 188:802.</a></li><li><a class="nounderline abstract_t">Shorey J, Schenker S, Suki WN, Combes B. Hepatotoxicity of mercaptopurine. Arch Intern Med 1968; 122:54.</a></li><li><a class="nounderline abstract_t">Berkovitch M, Matsui D, Zipursky A, et al. Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: pharmacokinetic characteristics. Med Pediatr Oncol 1996; 26:85.</a></li><li><a class="nounderline abstract_t">McILVANIE SK, MACCARTHY JD. Hepatitis in association with prolonged 6-mercaptopurine therapy. Blood 1959; 14:80.</a></li><li><a class="nounderline abstract_t">CLARK PA, HSIA YE, HUNTSMAN RG. Toxic complications of treatment with 6-mercaptopurine; two cases with hepatic necrosis and intestinal ulceration. Br Med J 1960; 1:393.</a></li><li><a class="nounderline abstract_t">Adamson PC, Zimm S, Ragab AH, et al. A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors. Cancer Chemother Pharmacol 1990; 26:343.</a></li><li><a class="nounderline abstract_t">Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111:641.</a></li><li><a class="nounderline abstract_t">Rosman M, Bertino JR. Azathioprine. Ann Intern Med 1973; 79:694.</a></li><li><a class="nounderline abstract_t">Romagnuolo J, Sadowski DC, Lalor E, et al. Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity. Can J Gastroenterol 1998; 12:479.</a></li><li><a class="nounderline abstract_t">Small P, Lichter M. Probable azathioprine hepatotoxicity: a case report. Ann Allergy 1989; 62:518.</a></li><li><a class="nounderline abstract_t">Barrowman JA, Kutty PK, Ra MU, Huang SN. Sclerosing hepatitis and azathioprine. Dig Dis Sci 1986; 31:221.</a></li><li><a class="nounderline abstract_t">Ménard DB, Gisselbrecht C, Marty M, et al. Antineoplastic agents and the liver. Gastroenterology 1980; 78:142.</a></li><li><a class="nounderline abstract_t">Griner PF, Elbadawi A, Packman CH. Veno-occlusive disease of the liver after chemotherapy of acute leukemia. Report of two cases. Ann Intern Med 1976; 85:578.</a></li><li><a class="nounderline abstract_t">Satti MB, Weinbren K, Gordon-Smith EC. 6-thioguanine as a cause of toxic veno-occlusive disease of the liver. J Clin Pathol 1982; 35:1086.</a></li><li><a class="nounderline abstract_t">Krivoy N, Raz R, Carter A, Alroy G. Reversible hepatic veno-occlusive disease and 6-thioguanine. Ann Intern Med 1982; 96:788.</a></li><li><a class="nounderline abstract_t">Larrey D, Fréneaux E, Berson A, et al. Peliosis hepatis induced by 6-thioguanine administration. Gut 1988; 29:1265.</a></li><li><a class="nounderline abstract_t">Council on Drugs. Evaluation of two antineoplastic agents: pipobroman (Vercyte) and thioguanine. JAMA 1967; 200:139.</a></li><li><a class="nounderline abstract_t">Ruymann FB, Mosijczuk AD, Sayers RJ. Hepatoma in a child with methotrexate-induced hepatic fibrosis. JAMA 1977; 238:2631.</a></li><li><a class="nounderline abstract_t">Fried M, Kalra J, Ilardi CF, Sawitsky A. Hepatocellular carcinoma in a long-term survivor of acute lymphocytic leukemia. Cancer 1987; 60:2548.</a></li><li><a class="nounderline abstract_t">Kumari TP, Shanvas A, Mathews A, Kusumakumary P. Hepatocellular carcinoma: a rare late event in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2000; 22:289.</a></li><li><a class="nounderline abstract_t">Leme PR, Creaven PJ, Allen LM, Berman M. Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man. Cancer Chemother Rep 1975; 59:811.</a></li><li><a class="nounderline abstract_t">Evans WE, Pratt CB. Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther 1978; 23:68.</a></li><li><a class="nounderline abstract_t">Avilés A, Herrera J, Ramos E, et al. Hepatic injury during doxorubicin therapy. Arch Pathol Lab Med 1984; 108:912.</a></li><li><a class="nounderline abstract_t">Benjamin RS, Wiernik PH, Bachur NR. Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer 1974; 33:19.</a></li><li><a class="nounderline abstract_t">Piscitelli SC, Rodvold KA, Rushing DA, Tewksbury DA. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 1993; 53:555.</a></li><li><a class="nounderline abstract_t">Johnson PJ, Dobbs N, Kalayci C, et al. Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters. Br J Cancer 1992; 65:751.</a></li><li><a class="nounderline abstract_t">Chan KK, Chlebowski RT, Tong M, et al. Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis. Cancer Res 1980; 40:1263.</a></li><li><a class="nounderline abstract_t">Doroshow J, Chan K. Relationship between doxorubicin clearance and indocyanine green dye pharmacokinetics in patients with hepatic dysfunction (abstract). Proc Am Soc Clin Oncol 1982; 1:11.</a></li><li><a class="nounderline abstract_t">Benjamin RS. A practical approach to adriamycin (NSC 123127) toxicology. Cancer Chemother Rep 1975; 6:191.</a></li><li><a class="nounderline abstract_t">Donelli MG, Zucchetti M, Munzone E, et al. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 1998; 34:33.</a></li><li><a class="nounderline abstract_t">Yarbro JW, Kennedy BJ. A comparison of the rate of recovery from inhibition of RNA synthesis in mouse liver and transplantable glioma. Cancer Res 1967; 27:1779.</a></li><li><a class="nounderline abstract_t">Gurevich I, Akerley W. Treatment of the jaundiced patient with breast carcinoma: case report and alternate therapeutic strategies. Cancer 2001; 91:660.</a></li><li><a class="nounderline abstract_t">Dobbs NA, Twelves CJ, Gregory W, et al. Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme. Eur J Cancer 2003; 39:580.</a></li><li><a class="nounderline abstract_t">Paciucci PA, Sklarin NT. Mitoxantrone and hepatic toxicity. Ann Intern Med 1986; 105:805.</a></li><li><a class="nounderline abstract_t">Vredenburgh JJ, McIntyre OR, Cornwell GG 3rd, et al. Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia. Med Pediatr Oncol 1988; 16:187.</a></li><li><a class="nounderline abstract_t">Chlebowski RT, Bulcavage L, Henderson IC, et al. Mitoxantrone use in breast cancer patients with elevated bilirubin. Breast Cancer Res Treat 1989; 14:267.</a></li><li><a class="nounderline abstract_t">Bedikian AY, Stroehlein J, Korinek J, et al. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with metastatic colorectal cancer. Am J Clin Oncol 1983; 6:45.</a></li><li><a class="nounderline abstract_t">Wiseman LR, Spencer CM. Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer. Drugs Aging 1997; 10:473.</a></li><li><a class="nounderline abstract_t">Blum RH, Carter SK, Agre K. A clinical review of bleomycin--a new antineoplastic agent. Cancer 1973; 31:903.</a></li><li><a class="nounderline abstract_t">Yagoda A, Mukherji B, Young C, et al. Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients. Ann Intern Med 1972; 77:861.</a></li><li><a class="nounderline abstract_t">Robert J, Barbier P, Manaster J, Jacobs E. Hepatotoxicity of cytostatic drugs evaluated by liver function tests and appearance of jaundice. Digestion 1968; 1:229.</a></li><li><a class="nounderline abstract_t">Lazarus HM, Gottfried MR, Herzig RH, et al. Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantation. Cancer 1982; 49:1789.</a></li><li><a class="nounderline abstract_t">Crooke ST, Bradner WT. Mitomycin C: a review. Cancer Treat Rev 1976; 3:121.</a></li><li><a class="nounderline abstract_t">van Hazel GA, Scott M, Rubin J, et al. Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination. Cancer Treat Rep 1983; 67:805.</a></li><li><a class="nounderline abstract_t">Buroker TR, Kim PN, Baker LH, et al. Mitomycin-C alone and in combination with infused 5-fluorouracil to the treatment of disseminated gastrointestinal carcinomas. Med Pediatr Oncol 1978; 4:35.</a></li><li><a class="nounderline abstract_t">Konits PH, Aisner J, van Echo DA, et al. Mitomycin C and vinblastine chemotherapy for advanced breast cancer. Cancer 1981; 48:1295.</a></li><li><a class="nounderline abstract_t">Bukowski RM, Schacter LP, Groppe CW, et al. Phase II trial of 5-fluorouracil, adriamycin, mitomycin C, and streptozotocin (FAM-S) in pancreatic carcinoma. Cancer 1982; 50:197.</a></li><li><a class="nounderline abstract_t">Tefft M, Traggis D, Filler RM. Liver irradiation in children: acute changes with transient leukopenia and thrombocytopenia. Am J Roentgenol Radium Ther Nucl Med 1969; 106:750.</a></li><li><a class="nounderline abstract_t">Ludwig R, Weirich A, Abel U, et al. Hepatotoxicity in patients treated according to the nephroblastoma trial and study SIOP-9/GPOH. Med Pediatr Oncol 1999; 33:462.</a></li><li><a class="nounderline abstract_t">Pritchard J, Raine J, Wallendszus K. Hepatotoxicity of actinomycin-D. Lancet 1989; 1:168.</a></li><li><a class="nounderline abstract_t">McClay E, Lusch CJ, Mastrangelo MJ. Allergy-induced hepatic toxicity associated with dacarbazine. Cancer Treat Rep 1987; 71:219.</a></li><li><a class="nounderline abstract_t">el Saghir NS, Hawkins KA. Hepatotoxicity following vincristine therapy. Cancer 1984; 54:2006.</a></li><li><a class="nounderline abstract_t">Hohneker JA. A summary of vinorelbine (Navelbine) safety data from North American clinical trials. Semin Oncol 1994; 21:42.</a></li><li><a class="nounderline abstract_t">Desai ZR, Van den Berg HW, Bridges JM, Shanks RG. Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol 1982; 8:211.</a></li><li><a class="nounderline abstract_t">Van den Berg HW, Desai ZR, Wilson R, et al. The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol 1982; 8:215.</a></li><li><a class="nounderline abstract_t">Robieux I, Sorio R, Borsatti E, et al. Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther 1996; 59:32.</a></li><li><a class="nounderline abstract_t">Kitzen JJ, Puozzo C, de Jonge MJ, et al. Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study. Eur J Cancer 2010; 46:266.</a></li><li><a class="nounderline abstract_t">Issell BF, Crooke ST. Etoposide (VP-16-213). Cancer Treat Rev 1979; 6:107.</a></li><li><a class="nounderline abstract_t">Tran A, Housset C, Boboc B, et al. Etoposide (VP 16-213) induced hepatitis. Report of three cases following standard-dose treatments. J Hepatol 1991; 12:36.</a></li><li><a class="nounderline abstract_t">Johnson DH, Greco FA, Wolff SN. Etoposide-induced hepatic injury: a potential complication of high-dose therapy. Cancer Treat Rep 1983; 67:1023.</a></li><li><a class="nounderline abstract_t">Chan HY, Meyers FJ, Lewis JP. High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia. Cancer Chemother Pharmacol 1987; 20:265.</a></li><li><a class="nounderline abstract_t">Perry MC, Moertel CG, Schutt AJ, et al. Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer. Cancer Treat Rep 1976; 60:1247.</a></li><li><a class="nounderline abstract_t">D'Incalci M, Rossi C, Zucchetti M, et al. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 1986; 46:2566.</a></li><li><a class="nounderline abstract_t">Arbuck SG, Douglass HO, Crom WR, et al. Etoposide pharmacokinetics in patients with normal and abnormal organ function. J Clin Oncol 1986; 4:1690.</a></li><li><a class="nounderline abstract_t">Hande KR, Wolff SN, Greco FA, et al. Etoposide kinetics in patients with obstructive jaundice. J Clin Oncol 1990; 8:1101.</a></li><li><a class="nounderline abstract_t">Aita P, Robieux I, Sorio R, et al. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. Cancer Chemother Pharmacol 1999; 43:287.</a></li><li><a class="nounderline abstract_t">Stewart CF, Arbuck SG, Fleming RA, Evans WE. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J Clin Oncol 1990; 8:1874.</a></li><li><a class="nounderline abstract_t">Stewart CF. Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations. Cancer Chemother Pharmacol 1994; 34 Suppl:S76.</a></li><li><a class="nounderline abstract_t">Joel SP, Shah R, Clark PI, Slevin ML. Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol 1996; 14:257.</a></li><li><a class="nounderline abstract_t">Liu B, Earl HM, Poole CJ, et al. Etoposide protein binding in cancer patients. Cancer Chemother Pharmacol 1995; 36:506.</a></li><li><a class="nounderline abstract_t">Huizing MT, Misser VH, Pieters RC, et al. Taxanes: a new class of antitumor agents. Cancer Invest 1995; 13:381.</a></li><li><a class="nounderline abstract_t">Cresteil T, Monsarrat B, Alvinerie P, et al. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 1994; 54:386.</a></li><li><a class="nounderline abstract_t">Hirth J, Watkins PB, Strawderman M, et al. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000; 6:1255.</a></li><li><a class="nounderline abstract_t">Baker AF, Dorr RT. Drug interactions with the taxanes: clinical implications. Cancer Treat Rev 2001; 27:221.</a></li><li><a class="nounderline abstract_t">Huizing MT, Vermorken JB, Rosing H, et al. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial. Ann Oncol 1995; 6:699.</a></li><li><a class="nounderline abstract_t">Panday VR, Huizing MT, Willemse PH, et al. Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Semin Oncol 1997; 24:S11.</a></li><li><a class="nounderline abstract_t">Venook AP, Egorin MJ, Rosner GL, et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 1998; 16:1811.</a></li><li><a class="nounderline abstract_t">Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994; 12:1621.</a></li><li><a class="nounderline abstract_t">Seidman AD, Hochhauser D, Gollub M, et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996; 14:1877.</a></li><li class="breakAll">DailyMed Drug Information: https://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on January 24, 2024).</li><li><a class="nounderline abstract_t">Hudis CA, Seidman AD, Crown JP, et al. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14:58.</a></li><li><a class="nounderline abstract_t">Burris HA. Optimal use of docetaxel (Taxotere): maximizing its potential. Anticancer Drugs 1996; 7 Suppl 2:25.</a></li><li><a class="nounderline abstract_t">Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16:187.</a></li><li class="breakAll">DailyMed drug information. Available at: https://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on May 16, 2011).</li><li><a class="nounderline abstract_t">Minami H, Kawada K, Sasaki Y, et al. Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice. Cancer Sci 2009; 100:144.</a></li><li><a class="nounderline abstract_t">Syn NL, Wang L, Wong AL, et al. Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study. Cancer Sci 2016; 107:173.</a></li><li><a class="nounderline abstract_t">Samur M. Docetaxel and liver dysfunction: is it absolutely contraindicated? Am J Clin Oncol 2001; 24:319.</a></li><li class="breakAll">DailyMed drug information. Available at: https://dailymed.nlm.nih.gov/dailymed/index.cfm (Accessed on May 16, 2011).</li><li class="breakAll">Witteveen, P, Marchetti, S, Mergui-Roelvink, M, et al. Eribulin mesylate pharmacokinetics in patients with hepatic impairment (Abstract # 2582). J Clin Oncol 2010; 28:224s. Abstraact available online at http://www.asco.org/ascov2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=74&amp;abstractID=48260 (Accessed on February 07, 2011).</li><li><a class="nounderline abstract_t">LoRusso PM, Venkatakrishnan K, Ramanathan RK, et al. Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res 2012; 18:2954.</a></li><li><a class="nounderline abstract_t">Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7:2182.</a></li><li><a class="nounderline abstract_t">Raymond E, Boige V, Faivre S, et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 2002; 20:4303.</a></li><li><a class="nounderline abstract_t">Venook AP, Enders Klein C, Fleming G, et al. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 2003; 14:1783.</a></li><li><a class="nounderline abstract_t">Meyerhardt JA, Kwok A, Ratain MJ, et al. Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2004; 22:1439.</a></li><li><a class="nounderline abstract_t">Kramar A, Gourgou-Bourgade S, Ychou M. Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan. J Clin Oncol 2005; 23:650; author reply 650.</a></li><li><a class="nounderline abstract_t">Cavalli F, Tschopp L, Sonntag RW, Zimmermann A. A case of liver toxicity following cis-dichlorodiammineplatinum(II) treatment. Cancer Treat Rep 1978; 62:2125.</a></li><li><a class="nounderline abstract_t">Hill JM, Loeb E, MacLellan A, et al. Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases. Cancer Chemother Rep 1975; 59:647.</a></li><li><a class="nounderline abstract_t">Pollera CF, Ameglio F, Nardi M, et al. Cisplatin-induced hepatic toxicity. J Clin Oncol 1987; 5:318.</a></li><li><a class="nounderline abstract_t">Hruban RH, Sternberg SS, Meyers P, et al. Fatal thrombocytopenia and liver failure associated with carboplatin therapy. Cancer Invest 1991; 9:263.</a></li><li class="breakAll">Christian MC. Two toxicities associated with carboplatin use: a. gross hematuria b. hepatic veno-occlusive disease. Department of Health &amp; Human Services bulletin, National Institutes of Health; National Cancer Institute, Bethesda, MD 1989.</li><li><a class="nounderline abstract_t">Fakih MG. 5-fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction. Oncology 2004; 67:222.</a></li><li><a class="nounderline abstract_t">Synold TW, Takimoto CH, Doroshow JH, et al. Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 2007; 13:3660.</a></li><li><a class="nounderline abstract_t">Grenader T, Goldberg A, Gabizon A. Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel. Anticancer Drugs 2009; 20:845.</a></li><li><a class="nounderline abstract_t">Haskell CM, Canellos GP, Leventhal BG, et al. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 1969; 281:1028.</a></li><li><a class="nounderline abstract_t">Oettgen HF, Stephenson PA, Schwartz MK, et al. Toxicity of E. coli L-asparaginase in man. Cancer 1970; 25:253.</a></li><li><a class="nounderline abstract_t">Muss HB, Spell N, Scudiery D, et al. A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphoma. Invest New Drugs 1990; 8:125.</a></li><li><a class="nounderline abstract_t">Douer D, Aldoss I, Lunning MA, et al. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia. J Clin Oncol 2014; 32:905.</a></li><li><a class="nounderline abstract_t">Fesler MJ, Becker-Koepke S, Di Bisceglie AM, Petruska PJ. Procarbazine-induced hepatotoxicity: case report and review of the literature. Pharmacotherapy 2010; 30:540.</a></li><li><a class="nounderline abstract_t">McMaster KR 3rd, Hennigar GR. Drug-induced granulomatous hepatitis. Lab Invest 1981; 44:61.</a></li><li><a class="nounderline abstract_t">THURMAN WG, BLOEDOW C, HOWE CD, et al. A phase I study of hydroxyurea. Cancer Chemother Rep 1963; 29:103.</a></li><li><a class="nounderline abstract_t">Heddle R, Calvert AF. Hydroxyurea induced hepatitis. Med J Aust 1980; 1:121.</a></li><li><a class="nounderline abstract_t">McDonald GB, Tirumali N. Intestinal and liver toxicity of antineoplastic drugs. West J Med 1984; 140:250.</a></li><li class="breakAll">Prescribing information for Arsenic trioxide available online at http://www.trisenox.com/pdf/TRISENOX_pi.pdf (Accessed on October 07, 2010).</li><li><a class="nounderline abstract_t">Ramalingam SS, Kummar S, Sarantopoulos J, et al. Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol 2010; 28:4507.</a></li><li class="breakAll">Prescribing information for belinostat available online at http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206256lbl.pdf?et_cid=34049616&amp;et_rid=789337055&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2014%2f206256lbl.pdf (Accessed on July 11, 2014).</li><li><a class="nounderline abstract_t">Kawai A, Araki N, Sugiura H, et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol 2015; 16:406.</a></li><li><a class="nounderline abstract_t">Paz-Ares L, López-Pousa A, Poveda A, et al. Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone. Invest New Drugs 2012; 30:729.</a></li></ol></div><div id="topicVersionRevision">Topic 2837 Version 109.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7565951" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Drug-induced hepatotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16007524" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The hepatotoxicity of antifungal medications in bone marrow transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18035197" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17453823" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 6-mercaptopurine (6-MP) entrapped stealth liposomes for improvement of leukemic treatment without hepatotoxicity and nephrotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6503301" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6786601" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Hepatic vascular lesions associated with dacarbazine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7379000" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hepatic veno-occlusive disease due to DTIC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3359400" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Fatal hepatic vascular toxicity of DTIC. Is it really a rare event?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7237453" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hepatic toxicity of DTIC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6883354" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Acute liver dystrophy with thrombosis of hepatic veins: a fatal complication of dacarbazine treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1846405" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hepatopathy-thrombocytopenia syndrome--a complication of dactinomycin therapy for Wilms' tumor: a report from the United Kingdom Childrens Cancer Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2427187" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Fatal necrosis of the liver during ABVD chemotherapy for Hodgkin's disease. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/509400" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Acute hepatic vein thrombosis occurring during therapy for Hodgkin's disease: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7053705" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hepatic veno-occlusive disease caused by 6-thioguanine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14510948" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3008617" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1937385" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Azathioprine hepatotoxicity after liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20406923" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18160247" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effect of preoperative chemotherapy on liver resection for colorectal liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18156931" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16648507" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19822514" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18779598" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Radiation-induced liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7148508" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Fatal hepatitis following irradiation and vincristine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/667811" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Hepatopathy following irradiation and adriamycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8749898" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Morphologic spectrum of drug-induced hepatic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2254635" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Criteria of drug-induced liver disorders. Report of an international consensus meeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9303497" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10781624" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Evaluation of abnormal liver-enzyme results in asymptomatic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30653226" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17539025" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26595058" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hepatitis B Virus Reactivation and Prophylaxis During Solid Tumor Chemotherapy: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27803003" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32716741" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25447850" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25964247" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25412906" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29447061" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26694960" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35700421" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Practical Implementation of Universal Hepatitis B Virus Screening for Patients With Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8538348" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7848891" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hepatitis C virus acute exacerbation during chemotherapy and radiotherapy for oesophageal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15191008" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Reactivation of hepatitis C virus after chemotherapy for colon cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22271089" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10576374" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11553266" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9107080" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9740089" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1596284" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hepatocyte toxicity of mechlorethamine and other alkylating anticancer drugs. Role of lipid peroxidation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5454367" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Massive hepatic necrosis after cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4642424" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Poor response in two cases of juvenile rheumatoid arthritis to treatment with cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7092009" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Cyclophosphamide hepatotoxicity in a patient with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3975725" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cyclophosphamide-associated hepatotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8246624" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Cyclophosphamide-induced hepatotoxicity in a patient with Wegener's granulomatosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3060893" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cyclophosphamide-induced liver necrosis: a possible interaction with azathioprine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6468474" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effect of liver failure on the pharmacokinetics of cyclophosphamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/362280" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : [Clinical aspects of the excretion of alkylating cyclophosphamide metabolites in the urine of tumor bearing patients].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16473644" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Hepatotoxicity of chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2853857" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : [Hepatotoxicity with etoposide-ifosfamide combination therapy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2853857" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : [Hepatotoxicity with etoposide-ifosfamide combination therapy].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1487409" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1487409" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11145236" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Population pharmacokinetics of temozolomide in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22850321" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20730617" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hepatic encephalopathy after treatment with temozolomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22141295" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Temozolomide induced liver injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22394496" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6366139" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157478" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13861044" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Liver damage after chemotherapy for leukemia and lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13538708" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Hepatotoxicity due to chlorambucil; report of a case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3376924" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Busulfan-induced hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5280623" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Jaundice after treatment of leukemia with busulphan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6860357" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Depletion in vitro of mitochondrial glutathione in rat hepatocytes and enhancement of lipid peroxidation by adriamycin and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5858571" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6354414" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4716783" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : CCNU (1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, NSC-79037) in the treatment of cancer. Phase II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4352784" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4371075" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Clinical antitumor activity and toxicity of streptozotocin (NSC-85998).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4879053" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6577264" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Cytosine arabinoside induced liver damage: histopathologic demonstration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6594185" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Hepatic dysfunction and jaundice following high-dose cytosine arabinoside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3461882" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1056159" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Drugs five years later: cytarabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3463209" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1554959" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : The effects of impaired liver function on the elimination of antineoplastic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5111743" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : 5-fluorouracil given once weekly: comparison of intravenous and oral administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11689577" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16044340" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14630678" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430071" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3155548" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2530317" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2143063" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2941140" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Liver pathology following hepatic arterial infusion chemotherapy. Hepatic toxicity with FUDR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2957943" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2961314" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21989666" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3160313" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Sclerosing cholangitis after continuous hepatic artery infusion of FUDR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16505413" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2877311" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Fatal liver cirrhosis associated with long-term arterial infusion of floxuridine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3155793" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Therapy for metastatic colorectal cancer with hepatic artery infusion chemotherapy using a subcutaneous implanted pump.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10528900" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Hepatic arterial chemotherapy in metastatic colorectal patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9625429" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Gemcitabine--a safety review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14561005" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Fatal cholestatic liver failure associated with gemcitabine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10894879" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20233917" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Toxicities of gemcitabine in patients with severe hepatic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30014884" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17914077" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Commentary: Oncologic drugs in patients with organ dysfunction: a summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14132534" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : HEPATOTOXICITY OF MERCAPTOPURINE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5659378" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Hepatotoxicity of mercaptopurine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8531858" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: pharmacokinetic characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13607581" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Hepatitis in association with prolonged 6-mercaptopurine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13810473" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Toxic complications of treatment with 6-mercaptopurine; two cases with hepatic necrosis and intestinal ulceration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2208575" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2802419" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4584569" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Azathioprine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9812167" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Cholestatic hepatocellular injury with azathioprine: a case report and review of the mechanisms of hepatotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2735558" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Probable azathioprine hepatotoxicity: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3943451" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Sclerosing hepatitis and azathioprine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7350020" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Antineoplastic agents and the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1068643" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Veno-occlusive disease of the liver after chemotherapy of acute leukemia. Report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6957419" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : 6-thioguanine as a cause of toxic veno-occlusive disease of the liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7091946" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Reversible hepatic veno-occlusive disease and 6-thioguanine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3198003" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Peliosis hepatis induced by 6-thioguanine administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Evaluation of two antineoplastic agents: pipobroman (Vercyte) and thioguanine</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/200767" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Hepatoma in a child with methotrexate-induced hepatic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2444327" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Hepatocellular carcinoma in a long-term survivor of acute lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10864067" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Hepatocellular carcinoma: a rare late event in childhood acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1175171" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/618710" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Effect of pleural effusion on high-dose methotrexate kinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6548368" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Hepatic injury during doxorubicin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4810094" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8387903" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1316777" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6244090" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Relationship between doxorubicin clearance and indocyanine green dye pharmacokinetics in patients with hepatic dysfunction (abstract)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : A practical approach to adriamycin (NSC 123127) toxicology</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9624235" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Pharmacokinetics of anticancer agents in patients with impaired liver function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6064957" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : A comparison of the rate of recovery from inhibition of RNA synthesis in mouse liver and transplantable glioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11241231" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Treatment of the jaundiced patient with breast carcinoma: case report and alternate therapeutic strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12628836" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3767174" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Mitoxantrone and hepatic toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3380061" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Mitoxantrone in relapsed or refractory acute nonlymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2692728" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Mitoxantrone use in breast cancer patients with elevated bilirubin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6837506" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9205852" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Mitoxantrone. A review of its pharmacology and clinical efficacy in the management of hormone-resistant advanced prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4122362" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : A clinical review of bleomycin--a new antineoplastic agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4118759" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5696244" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Hepatotoxicity of cytostatic drugs evaluated by liver function tests and appearance of jaundice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7042075" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/786455" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Mitomycin C: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6411337" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/342890" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Mitomycin-C alone and in combination with infused 5-fluorouracil to the treatment of disseminated gastrointestinal carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6791808" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Mitomycin C and vinblastine chemotherapy for advanced breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6211223" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Phase II trial of 5-fluorouracil, adriamycin, mitomycin C, and streptozotocin (FAM-S) in pancreatic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4308791" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Liver irradiation in children: acute changes with transient leukopenia and thrombocytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10531570" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Hepatotoxicity in patients treated according to the nephroblastoma trial and study SIOP-9/GPOH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2563091" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Hepatotoxicity of actinomycin-D.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3802121" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Allergy-induced hepatic toxicity associated with dacarbazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6090004" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Hepatotoxicity following vincristine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7973769" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : A summary of vinorelbine (Navelbine) safety data from North American clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6125275" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Can severe vincristine neurotoxicity be prevented?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7105384" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8549031" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Pharmacokinetics of vinorelbine in patients with liver metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19944596" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/385138" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Etoposide (VP-16-213).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2007774" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Etoposide (VP 16-213) induced hepatitis. Report of three cases following standard-dose treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6315228" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Etoposide-induced hepatic injury: a potential complication of high-dose therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3677301" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/797447" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3697995" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3772420" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Etoposide pharmacokinetics in patients with normal and abnormal organ function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2348225" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Etoposide kinetics in patients with obstructive jaundice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10071979" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2230875" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Changes in the clearance of total and unbound etoposide in patients with liver dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8070032" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Use of etoposide in patients with organ dysfunction: pharmacokinetic and pharmacodynamic considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8558207" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Predicting etoposide toxicity: relationship to organ function and protein binding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7554043" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Etoposide protein binding in cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7627725" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Taxanes: a new class of antitumor agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7903909" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10778948" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11545542" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Drug interactions with the taxanes: clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8664192" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9314297" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9586895" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7913721" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8656256" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8656256" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8558221" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8862707" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Optimal use of docetaxel (Taxotere): maximizing its potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9440742" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9440742" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19018756" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Population pharmacokinetics of docetaxel in patients with hepatic dysfunction treated in an oncology practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26663719" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11404510" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Docetaxel and liver dysfunction: is it absolutely contraindicated?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11404510" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : Docetaxel and liver dysfunction: is it absolutely contraindicated?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11404510" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Docetaxel and liver dysfunction: is it absolutely contraindicated?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22394984" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11489791" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12409328" id="rid200" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>201 : Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14630685" id="rid201" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>202 : A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15084617" id="rid202" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>203 : Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15659517" id="rid203" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>204 : Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/751721" id="rid204" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>205 : A case of liver toxicity following cis-dichlorodiammineplatinum(II) treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1203889" id="rid205" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>206 : Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3806175" id="rid206" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>207 : Cisplatin-induced hepatic toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1913229" id="rid207" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>208 : Fatal thrombocytopenia and liver failure associated with carboplatin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1913229" id="rid208" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>209 : Fatal thrombocytopenia and liver failure associated with carboplatin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15557782" id="rid209" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>210 : 5-fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17575231" id="rid210" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>211 : Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19633535" id="rid211" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>212 : Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4898857" id="rid212" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>213 : L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4905153" id="rid213" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>214 : Toxicity of E. coli L-asparaginase in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2345067" id="rid214" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>215 : A phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24516026" id="rid215" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>216 : Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20412004" id="rid216" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>217 : Procarbazine-induced hepatotoxicity: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7453131" id="rid217" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>218 : Drug-induced granulomatous hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13981319" id="rid218" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>219 : A phase I study of hydroxyurea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7374520" id="rid219" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>220 : Hydroxyurea induced hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6375139" id="rid220" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>221 : Intestinal and liver toxicity of antineoplastic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6375139" id="rid221" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>222 : Intestinal and liver toxicity of antineoplastic drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20837947" id="rid222" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>223 : Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20837947" id="rid223" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>224 : Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25795406" id="rid224" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>225 : Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20960029" id="rid225" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>226 : Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
